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Alcohol use disorder (AUD) – defined according to the Diagnostic and Statistical Manual 
of Mental Disorders, Fifth Edition (DSM-5) criteria. It is a maladaptive pattern of alcohol use 
leading to clinically significant impairment or distress, as manifested by 2 or more of the 
following 11 criteria occurring at any time in the last 12 months: role impairment; hazardous 
use; social problems; tolerance; withdrawal; longer or more use than intended; unsuccessful 
attempts to quit/cut down; much time spent using alcohol; reduced activities because of 
drinking; continued drinking despite psychological or physical problems; and alcohol cravings. 
Area deprivation level – based on the Irish Pobal HP deprivation index that was developed 
by Haase and Pratschke. The index is a method of measuring the relative affluence or 
deprivation of a geographical area using data compiled from various censuses. A score is 
given to the area based on a national average of 0 and ranging from −35 (being the most 
deprived) to +35 (being the least deprived). For the purposes of this report, these data are 
presented in five quintiles, from most deprived (1) to least deprived (5).
Cannabis use disorder (CUD) – defined as any cannabis abuse or dependence in the 
12 months prior to the survey, and classified according to the Diagnostic and Statistical 
Manual of Psychiatric Disorders, Fourth Edition (DSM-IV). Cannabis abuse is established 
from a positive response in one or more of the four domains in the DSM-IV diagnostic 
criteria: hazardous use; role impairment; legal problems related to use; or social or 
interpersonal problems. Cannabis dependence is determined from a positive response in 
three or more of the following seven domains: tolerance; withdrawal; longer or more use 
than intended; unsuccessful attempts to quit/cut down; much time spent obtaining cannabis 
or recovering from its effects; giving up or reducing important social, occupational, or 
recreational activities in favour of use; or continued use despite psychological or physical 
problems.
Ex-drinker – a person who has consumed alcohol beyond sips or tastes in their lifetime, but 
who has not consumed alcohol in the last year.
Heavy episodic drinking (HED) – sometimes referred to as ‘binge drinking’ and defined as 
consuming six or more standard drinks on a single occasion. This is approximately equivalent 
to three pints of beer or cider, six pub measures of spirits, or just under one bottle of wine.
Illegal drugs – defined as any of the following: cannabis, ecstasy, cocaine powder, magic 
mushrooms, amphetamines, poppers, LSD, new psychoactive substances (NPS), solvents, 
crack, and heroin. Poppers and solvents are not actually illegal in Ireland, however, to ensure 
comparability with previous surveys they have been included in this category.
Last month prevalence – refers to the proportion of the sample that reported using a 
named drug in the 30-day period prior to the survey. Last month prevalence is often 
referred to as current use. A proportion of those reporting current use may be occasional (or 
first-time) users who happen to have used in the period leading up to the survey. It should 
therefore be noted that current use is not synonymous with regular use.
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Last year prevalence – refers to the proportion of the sample that reported using a named 
drug in the year prior to the survey. Last year prevalence is often referred to as recent use. 
Lifetime prevalence – refers to the proportion of the sample that reported ever having used 
the named drug at the time they were surveyed. A person who records lifetime prevalence 
may or may not be currently using the drug. Lifetime prevalence should not be interpreted as 
meaning that people have necessarily used a drug over a long period of time or that they will 
use the drug again in future. 
New psychoactive substances (NPS) – refers to a new narcotic drug or a new psychotropic 
drug in its pure form or in a preparation. Many of these substances mimic the most common 
illegal drugs, namely cocaine, ecstasy, amphetamine, and cannabis.
Never drinker – a person who has never consumed alcohol beyond sips or tastes in their lifetime. 
Never smoker – a person who does not currently smoke and has never smoked in their lifetime.
Non-drinker – a person who has not consumed alcohol in the last year. This can be a person 
who has never consumed alcohol in their lifetime or who has most recently consumed 
alcohol more than a year ago.
Non-medical use of prescribable drugs – the use of these medicines without a personal 
prescription, taking more tablets than prescribed, or taking tablets for a longer period or for 
different purposes than prescribed.
Opioid pain relievers – medicines that contain opioids such as codeine or morphine. Most 
of these products require a prescription, although some codeine products are available from 
a pharmacist without a prescription (for example, Solpadeine and Nurofen Plus). 
Polydrug use – the use of more than one drug. It can be simultaneous, which is the use of 
two or more drugs on the same occasion, or concurrent, which is the use of two or more 
different substances in a given time period, such as during the last month or the last year.
Prescribable drugs – drugs that can be legally purchased from a pharmacy or chemist, 
usually with a prescription.
Prevalence – refers to the proportion of a population that has used a drug over a particular 
time period. 
Sedatives and tranquillisers – medicines that can be obtained from a doctor and which are 
sometimes prescribed to help people sleep, calm down, or to relax their muscles.
Smoker – a person who reports currently smoking either daily or occasionally. 
Standard drink – a drink that contains 10 grams of alcohol; this is the equivalent of one glass 
of beer, one pub measure of spirits, or 100 mL of wine. 
Statistically significant – a result is deemed statistically significant if it is unlikely to have 
occurred by chance, and hence provides enough evidence to reject the hypothesis of ‘no 
effect’. As used in statistics, ‘significant’ does not mean important or meaningful. A small, 
but important, real-world difference may fail to reach significance in a statistical test, while a 
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The National Drug and Alcohol Survey (NDAS) collects information on alcohol and tobacco 
consumption and drug use among the general population in Ireland. It also surveys people’s 
attitudes and perceptions relating to tobacco, alcohol, and other drug use and records the 
impact of drug use on people’s communities. The 2019–20 NDAS collected information from 
5,762 people aged 15 years and older across Ireland.
1.1 National drugs strategy
An Taoiseach Leo Varadkar launched Reducing Harm, Supporting Recovery: A health-led 
response to drug and alcohol use in Ireland 2017–2025 on 17 July 2017. The strategy was 
presented as a health-led rather than a criminal justice approach to drug use and was the 
first strategy in Ireland to adopt an integrated public health approach to drug and alcohol 
use. The strategy defines substance misuse as “the harmful or hazardous use of psychoactive 
substances, including alcohol, illegal drugs and the abuse of prescription medicines”.1 While 
the strategy complements the Public Health (Alcohol) Act 2018 and strengthens some of the 
key parts of the alcohol-focused Steering Group Report on a National Substance Misuse 
Strategy from 2012,2 illegal drug use is the primary focus of many of the actions of the current 
strategy. The strategy covers an 8-year period (2017–2025) and is accompanied by a shorter-
term action plan (2017–2020). The strategy’s vision is for “A healthier and safer Ireland, where 
public health and safety is protected and the harms caused to individuals, families and 
communities by substance misuse are reduced and every person affected by substance use 
is empowered to improve their health and wellbeing and quality of life.”
The Minister for Health continues to have overall ministerial responsibility for the national 
drugs strategy. The Department of Health also has a Minister of State who combines 
responsibility for the national drugs strategy with other policy areas within the health 
portfolio. Implementation of the strategy is coordinated through a National Oversight 
Committee, comprising senior members of the various stakeholder groups; a standing 
subcommittee; and various subcommittees established by the National Oversight Committee. 
One of the national drugs strategy’s five strategic goals is to develop sound and 
comprehensive evidence-informed policies and actions. The Drugs Policy and Social 
Inclusion Unit in the Department of Health analyses the implications of research findings 
for policy and the design of initiatives to tackle the drug problem, and advises on the 
commissioning of new research and development of new data sources. 
1.2 Role of the Health Research Board
The Health Research Board (HRB) manages the commissioning of research and monitoring 
projects on behalf of the Department of Health and as part of its role as the Irish national 
focal point to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
The EMCDDA provides factual, objective, reliable, and comparable information concerning 
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drugs, drug addiction, and their consequences. The Centre monitors the drugs situation 
and responses to drug-related problems in Europe. Prevalence and patterns of drug use 
is one of the five key epidemiological indicators used by the EMCDDA to assess the drug 
situation in Europe. This indicator uses a number of approaches including general population 
surveys and school population drug surveys, as well as innovative new approaches such as 
wastewater-based drug epidemiology, and targeted surveys, including web surveys. This 
helps with understanding patterns of use, risk perceptions, and social and health correlates, 
as well as the consequences of the use of illegal drugs. General population surveys are one 
of the key tools used by European Union member states to develop knowledge around this 
indicator. The 2019–20 NDAS is the fifth such study undertaken in Ireland. It will provide vital 
information to assess the current drug situation, map trends since 2002-03, and inform the 
development of responses to this situation in the coming years.
The most recent drugs strategy report, Reducing Harm, Supporting Recovery: A health-led 
response to drug and alcohol use in Ireland 2017–2025, has designated the HRB the main 
information hub for evidence on the drugs situation and responses.1 Action 5.1.45 (strengthen 
Ireland’s drug monitoring system) of this strategy gives the HRB responsibility for the EMCDDA 
indicators pertaining to prevalence and patterns of drug use among the general population.
1.3 About the NDAS 
The rationale for the 2019–20 NDAS was to generate data that estimate the prevalence 
of drug use and describe patterns of use, as set out in action 5.1.45 of the national drugs 
strategy. The objective of the 2019–20 NDAS was to determine the prevalence and patterns 
of drug use (including alcohol and tobacco use) of a representative sample of the general 
population aged 15 years and older in Ireland, and to compare the current situation with 
previous surveys. The data collected provide:
1. A profile of tobacco use, including e-cigarettes, in Ireland
2.  A detailed description of drinking patterns (including hazardous drinking patterns) in 
Ireland, and the harms associated with alcohol use
3.  Prevalence estimates of lifetime, last year, and last month use of illegal and prescribable drugs
4. A description of drug use according to sex, age, and area deprivation level
5. An estimation of the prevalence of alcohol use disorder and cannabis use disorder
6.  Findings on the perceptions and attitudes of people in Ireland towards tobacco, alcohol, 
and drug use, and
7. Information on the impact of drug use on local communities.
Previous drug prevalence surveys were undertaken in 2002–03, 2006–07, 2010–11, and 
2014–15. These surveys were commissioned on an all-island basis by the National Advisory 
Committee on Drugs and Alcohol (NACDA) in the Republic of Ireland, and the Department 
of Health, Social Services and Public Safety in Northern Ireland. For the first time, the 
current survey was managed by the HRB and only included the Republic of Ireland. The 
HRB commissioned Ipsos MRBI to organise, collect and validate the NDAS. Ipsos MRBI also 
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undertook this role for the first four surveys. A research advisory group supported the HRB 
in the management of the survey.
1.4 Report structure
1.4.1 Layout of report
This report outlines the results of the 2019–20 NDAS at a national level and compares them 
with those of previous surveys. Prevalence estimates will be published for the 10 Regional 
Drug and Alcohol Taskforce areas at a later stage. Following this introductory chapter, 
Chapter 2 describes the methodology employed for this survey. Chapters 3 and 4 give 
information on the use of tobacco and alcohol. Chapter 5 describes the use of illegal drugs 
with Chapter 6 providing more detailed sections on cannabis, ecstasy, and cocaine use, 
and Chapter 7 covers the use of prescribable drugs, including non-medical use. Chapter 8 
presents findings on the perceptions and attitudes of people in Ireland towards tobacco, 
alcohol, and drug use, and the impact of drug use on communities is described in Chapter 
9. Appendix I contains detailed tables on the lifetime, last year, and last month prevalence 
of use for each substance included in the survey. These are presented for the total sample, 
and separately by age group and sex, and 95% confidence intervals are provided for these 
estimates. Appendix II presents trends in lifetime, last year, and last month prevalence of use 
for each substance, by age group and sex, across the five surveys completed to date. 
1.4.2 Understanding the results in this report
Trends over the five survey time points are presented in Appendix II and also throughout the 
report. As the population for the first three surveys excluded adults aged 65 years and older, 
trends are only presented for adults aged 15–64 years. All tables in Appendix II have been 
tested for statistically significant changes between each survey but this has not been done 
for other comparisons throughout the report (such as between sex or age). Where it is stated 
in the text that there has been a significant change in prevalence, this means that the change 
is statistically significant.
All prevalence rates presented in this report are based on weighted responses and are 
rounded to one decimal place. Percentages may not always sum to 100 due to either the 
effect of rounding or where respondents could give more than one answer.
When the figure 0.0% is reported in the prevalence tables it can mean that either no 
respondents reported use of the drug or that a very low number reported use and that due to 
rounding it is presented as 0.0%. This does not mean that no-one in the population has used 
the drug, rather it means that the sample was too small to detect prevalence. In Appendix I, 
confidence intervals are only provided after 0.0% if there are observations in the category. 
Where there are no confidence intervals, this means that there were no observations.
Where population estimates are provided, they are presented to the nearest thousand.
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This chapter outlines the methodology employed to undertake the 2019–20 NDAS. It 
describes the survey design, questionnaire development, sampling, fieldwork, and data 
processing that was undertaken. A more detailed account of the NDAS methodology is 
provided in the survey’s technical report, which may be accessed at www.drugsandalcohol.ie.
2.1 Survey design
The design of the NDAS was guided by best practice guidelines drawn up by the EMCDDA.3 
The universe for the survey was defined as all adults aged 15 years and older living in private 
households in the Republic of Ireland. Excluded from this survey were persons who do not 
normally live in private households – for example, members of the Traveller community; 
people who were homeless; or those in institutions, such as prisons or nursing homes. The 
survey did not make a specific provision for interviews to be conducted in languages other 
than English. The survey data were recorded face-to-face in respondents’ homes using the 
Computer-Assisted Personal Interviewing (CAPI) technique. Compared with the pen-and-
paper method, CAPI reduces the number of missed questions and logical errors at the 
time of data collection, as the programme automatically guides interviewers to the correct 
question. It also reduces the time required to complete each interview, as it skips to the next 
appropriate question for each interviewee. 
2.2 Questionnaire development
Similar to the four previous surveys, the 2019–20 NDAS was based on the EMCDDA model 
questionnaire.3 In order to enable comparisons over time, the questionnaire for the 2014–15 
survey was used for the current survey, with a number of new questions added. These new 
questions were as follows: 
•  A module on the non-medical use of sedatives/tranquillisers and opioid pain relievers was 
added; the included questions were proposed by the EMCDDA in 2018. 
•  A question on polydrug use – defined as the use of two or more substances at one time 
(simultaneous use) – was asked of those who reported last year use of alcohol, cannabis, 
ecstasy, or cocaine.
•  A set of questions was included on the impact of drug use and drug dealing – including 
drug-related intimidation – on local communities. 
•  For each respondent, the deprivation level of the area they live in was recorded for 
the first time in the NDAS. The deprivation index used in the NDAS is based on the Irish 
Pobal HP deprivation index that was developed by Haase and Pratschke.4 The index is a 
method of measuring the relative affluence or deprivation of a geographical area using 
data compiled from various censuses. For the purposes of this report, these data are 
presented in five quintiles, from most deprived (1) to least deprived (5).
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Prior to the fieldwork, cognitive testing was undertaken to evaluate questionnaire content in 
order to ensure that respondents would understand questions in the way that was intended 
by the researchers. The approach used by Ipsos MRBI to test this questionnaire involved 
‘think-aloud interviewing’, whereby the respondent is asked to talk through their thought 
process as they arrive at an answer, and ‘verbal probing’, whereby the respondent is required 
to provide further information on their answer. Following this exercise, a number of minor 
changes to question wording and to the showcards were undertaken. The questionnaire was 
then converted into a CAPI script suitable for interviewing. At this stage, the questionnaire 
was tested using CAPI in order to ensure that all questions were included with the correct 
wording and in the correct order, and also to check the routing. A series of pilot interviews 
with members of the general public were then conducted in December 2018. 
2.3 Sampling
The survey used stratified and multistage area probability sampling methods to select a 
representative sample of the Irish population that was aged 15 years and older and was living 
in private households.
2.3.1 Sampling frame
The sampling frame was An Post/Ordnance Survey Ireland’s GeoDirectory, which was also 
used in the previous four surveys GeoDirectory is a complete database of every building in 
the Republic of Ireland. Each of the 2.2 million addresses contained in GeoDirectory includes 
an accurate standardised postal address, usage details for each building (commercial or 
residential), a unique 8-digit identity number, Eircode, and geo-coordinates which accurately 
locate the centre point of each building to within one metre. The advantages of the 
GeoDirectory are that it is comprehensive and regularly updated, and has a high degree of 
accuracy. It avoids double counting, as buildings which have alternative names are counted 
only once, and it also provides separate lists for businesses and residential addresses. It links 
every address to its electoral division (ED), allowing for the separation of data from large (e.g. 
Regional Drug and Alcohol Task Force (RDATF) areas) and small (e.g. EDs) geographical areas. 
However, using the GeoDirectory has some limitations: it does not include dwellings that have 
been built but not yet added to the database; addresses may be listed without dwellings; and 
dwellings may contain multiple households. 
2.3.2 Selection of sample
As well as providing national estimates of drug use prevalence, the sample needed to be 
sufficiently large and structured in such a way as to facilitate comparisons between the 10 
RDATF areas. Similar to the previous four surveys, sampling was undertaken by RDATF area 
to enable the estimation of drug use prevalence in each area and to allow for monitoring of 
drug prevalence trends over time. To provide reliable measurements by RDATF area, it was 
calculated that 650 completed interviews in each of the 10 RDATF areas would be required. 
A three-stage process was used to construct the sample for this survey. Stratification 
techniques were used to select primary sampling units (PSUs). In this survey, EDs were 
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defined as PSUs. In the first stage of stratification, the number of addresses for each 
RDATF was agreed at between 980 and 1,344. The exact number of selected addresses was 
determined by the expected response rate in each area based on the achieved response 
rate on the previous iteration of this survey (Table 1).






















East Coast 50.3% 55.0% 1,344 1,200 660
North Dublin 42.2% 55.0% 1,344 1,200 660
South Western 50.1% 55.0% 1,344 1,200 660
Midland 74.3% 70.0% 1,036 925 647
Mid-West 58.8% 58.0% 1,260 1,125 652
North Eastern 61.1% 60.0% 1,260 1,125 675
Southern 64.2% 64.0% 1,148 1,025 656
Northwest 71.1% 70.0% 1,036 925 647
South East 72.0% 70.0% 1,036 925 647
Western 82.6% 75.0% 980 875 656
Total 60.4% 62.3% 11,788 6,560
In the second stage of stratification, 421 PSUs were randomly selected. The decision on 
the number of PSUs selected was based on practical considerations (an appropriate 
compromise between allowing a sufficient range of coverage and the need to be practical 
from a data collection and field management perspective). These PSUs were then ranked by 
sociodemographic indicators (degree of urban/rural respondents and proportion of owner 
occupiers) to ensure that a representative cross-section of areas was included. In this way, 
PSUs of all sizes and compositions would have an equal chance of selection. Twenty-eight 
addresses were randomly selected from each of the 421 PSUs. A household was defined as 
a person, or as a group of people who normally live at the same property and who share 
a living room or at least one meal a day. In properties with multiple households, one was 
randomly selected using a Kish grid. Individuals (aged 15 years and older) within each selected 
household were randomly selected to take part in the survey. This was done by listing all 
individuals aged 15 years and older living in the household and then randomly selecting one 
using the CAPI device. 
The 2019–20 Irish National Drug and Alcohol Survey
10
2.4 Fieldwork
Fieldwork commenced in February 2019. Prior to this, a series of interviewer briefings were 
conducted in order to ensure that interviewers were fully prepared to conduct the survey. 
The initial interviewer briefing was held in Dublin on 23 January 2019. Further briefings were 
held throughout the fieldwork period. The briefings provided opportunities for discussion 
and role play, as well as a thorough run-through of the survey.
Two letters from the HRB and Ipsos MRBI were sent in advance of fieldwork to the entire 
selected sample, outlining that a survey was taking place and that an interviewer would call 
to their door. The letters contained a respondent information sheet providing information on 
the household selection process, the survey content, the voluntary nature of participation, 
contact details in case of queries pertaining to the survey, and support services should 
the respondent require help on issues relating to the problems caused by drug use. Signed 
consent was obtained from all participants. In providing this consent, respondents were 
informed that their participation in the survey was voluntary, anonymous, and confidential, 
and that they were free to refuse to answer any particular question, to stop the interview 
at any point, and to request that all data they provided to Ipsos MRBI be destroyed. 
Written consent from a parent or guardian was required for all young people aged 15–17 
years. The parent or guardian also had the right to sit in on the interview if they so wished. 
Data collection was conducted using tablet devices. Sensitive questions, including those 
that measured cannabis use disorder and alcohol use disorder, were self-completed by 
respondents. 
In order to monitor progress and calculate response rates, interviewers completed a contact 
sheet for each address that was issued to them. Interviewers uploaded completed interviews 
on a daily basis, so as to ensure that interim data files could be produced in order to check 
the quality and integrity of the data. Validation of 90 completed assignments was conducted 
by telephone. 
All interviews were conducted face to face in respondents’ homes. An exception to this was 
an exercise that was undertaken to enhance response rates among certain household types 
in Dublin. Lower response rates among those living in apartments is a common feature of 
pre-select surveys due to the difficulties in accessing these households. In order to improve 
the response rate, addresses that were located in apartment or shared buildings were sent 
a letter asking them to contact Ipsos MRBI to participate in the research. One individual in 
each household was then randomly selected and invited to an interview session in a central 
location in Dublin. Each individual who participated in this exercise received a €50 voucher 
to compensate them for the expenses they incurred in order to attend.
Over the course of the fieldwork period, 22,828 contacts were made with the 11,788 
households that were selected. This equates to an average of 1.94 contacts per household. 
Most of these were in-person visits, although this also includes contact by letter after face-
to-face fieldwork was halted due to Covid-19. The achieved sample was 5,762, which is 87.8% 
of the initial target of 6,560.
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2.4.1 Impact of Covid-19 on fieldwork
Due to the onset of the Covid-19 crisis in March 2020 and the restrictions on movement that 
followed, the decision was made to halt interviewing in the interest of the safety of interviewers 
and respondents. At that point, 5,640 interviews had been completed. There were also various 
incomplete sample assignments that were already in progress, and those that had not yet 
commenced. In order to maximise the number of completed interviews, a letter was sent to 
all remaining households, as well as selected non-responding households, that introduced the 
survey and asked a member of each household to contact Ipsos MRBI on a freephone telephone 
number in order to participate. Upon making contact, a member of Ipsos MRBI completed the 
respondent selection process within the household and then invited the selected individual to 
complete an interview over the telephone. The self-completion modules were not administered 
to respondents completing the survey over the phone. Those participating in the survey received 
a €20 voucher to compensate them for their time. Over the course of this exercise in April and 
May 2020, 2,278 letters were issued, resulting in 127 interviews.
2.5 Ethical approval 
Ethical approval for the survey was obtained from the Royal College of Physicians of Ireland.
2.6 Response rate
Table 2 details the response rate for the households that were sampled.




Complete interview Full interview 5,762
Unproductive addresses No reply after five contacts 646
Appointment not maintained by respondent 260
Partial interview 31
Other reason address was unproductive 224
Refusal Refusal to interviewer 1,948
Refusal by contacting office 149





Ineligible addresses Property vacant 760
Occupied but not main residence  
(e.g. holiday home) 163
Non-residential address 280
Address inaccessible 825
Address not found 70
Communication difficulties 220
No response to letter following  
curtailment of fieldwork 450
Total 11,788
The response rate was calculated by dividing the number of complete interviews by the 
sum of all addresses minus ineligible addresses. The response rate was therefore 63.9%. 
However, two significant issues should be noted here. First, the proportion of ineligible 
addresses was higher in this wave than in the four previous survey waves. Overall, 2,768 
out of 11,788 addresses were classified by interviewers as being ineligible. This accounts for 
23.5% of the total sample, compared with 12.4% of the total sample for the 2014–15 survey. 
Part of this is accounted for by differences in the way the sample was created, as this wave’s 
sample contained a higher proportion of non-residential addresses and vacant addresses 
than would normally be expected. Also, 450 addresses that did not receive any interviewer 
contact before fieldwork was curtailed due to Covid-19 restrictions, and that also did not 
respond to a follow-up letter are classified as ineligible because their eligibility has not 
been established. It is likely that most of these addresses would have been eligible, but it 
is not known how many would have agreed to participate in the survey. As a result they are 
classified as ineligible. This has the effect of inflating the response rate.
Further analysis of the response rate indicates a much lower response rate in the North 
Dublin RDATF (41.0%) compared with in the Western RDATF (84.8%) and in the Midland RDATF 
(83.1%) (Table 3). This is comparable to other surveys and is addressed through the post-
survey weighting structure that is applied.
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interview 537 399 587 745 467 592 619 556 574 686
Unproductive 
addresses 104 203 114 47 86 129 82 84 245 67
Refusal 348 372 240 104 314 228 98 167 170 56
Ineligible 
addresses 348 375 405 140 393 311 237 229 159 171
Response 
rate 54.3% 41.0% 62.4% 83.1% 53.9% 62.4% 77.5% 68.9% 58.0% 84.8%
2.7 Weighting
Weighting of the achieved sample was required in order to account for differential response 
rates and the sampling approach used in this survey. Younger males and those living in large 
urban areas were under-represented, while the sampling approach whereby one individual 
was selected at random within a household meant that those living in households with fewer 
people were more likely to be selected than those living in households with more people.
The first stage in the weighting process was to generate a selection weight in order to 
address any issues that may arise due to those living in smaller households being more likely 
to be selected. In doing so a weight was calculated that was the inverse of the selection 
probabilities – i.e. those living in larger households had a higher weight applied than those 
living in smaller households. 
The second stage in this process was to overcome discrepancies arising from differential 
response rates. In doing so, the weighting variables should relate to both the likelihood of 
participating and health behaviours. Weights were produced according to the following 
variables: age by sex; education; working status; and region. Population information was taken 
from the Central Statistics Office, and a rim weighting process was used.
A small number (around 0.5%) of high weights were capped in order to prevent extreme 
weights. The final weights were scaled to give a mean of 1 and ensure that the weighted 
sample size matches the unweighted sample size. The weighting scheme resulted in a design 
effect of 1.54 and an effective base size of 3,743.
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2.8 Data analysis
The data were analysed by age and sex, by age within sex, and by area deprivation level. Data 
are presented using weighted proportions. Confidence intervals of 95% were calculated 
for key statistics and are presented in Appendix I. They provide a range of likely prevalence 
rates for all categories of drug use. The confidence interval calculation takes into account 
the effects of the weighting, stratification, and clustering. In order to identify whether or not 
changes in prevalence since the 2014–15 survey could be considered statistically significant, a 
straightforward p-value test was conducted. A p-value was calculated for each variable using 
the survey result and associated standard error. All changes with a p-value of less than 0.05 
were considered to be statistically significant. The prevalence of cannabis use disorder and 
alcohol use disorder were measured using DSM criteria. The sampling procedures employed 
in this survey facilitate the estimation of drug prevalence at RDATF level. In this report we 
have concentrated mainly on national estimates. Drug prevalence estimates for each RDATF 
area will be published at a later stage in 2021.
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3.1 Tobacco: Main findings
The main findings from the 2019–20 NDAS regarding tobacco use include the following:
•  17.4% of respondents indicated current tobacco use, corresponding to 680,000 of the 
general population in Ireland aged 15 years and older; 1 in 4 (25.6%) respondents, or 
1,000,000 of the general population, were ex-smokers.
•  This was the first NDAS where the proportion of ex-smokers was found to be greater than 
the proportion of current smokers.
•  The main reasons reported for quitting smoking were its effect on health or fitness 
(27.8%), cost (13.3%), and health warning labels (12.7%).
• Males (20.6%) were more likely than females (14.3%) to report current smoking.
• 24.7% of smokers reported smoking at least 20 cigarettes per day.
•  4.3% (167,000) of the adult population reported current e-cigarette use; this has 
increased from 3.1% reported in 2014–15.
• The average age of first smoking tobacco was 17.4 years (median: 16 years).
• The average age of current smokers was 42.4 years (median: 41 years).
•  The median age at which 15–24-year-olds initiated smoking has increased from 15 years to 
16 years since 2002–03.
3.2 Tobacco use in Ireland 
In 2019–20, 17.4% of respondents reported current smoking, corresponding to 680,000 of 
the general population in Ireland aged 15 years and older; 13.9% of respondents reported 
daily smoking and 3.5% reported occasional smoking. A further 25.6%, or 1,000,000 of the 
general population, were ex-smokers. There has been a statistically significant decrease in 
current tobacco use since 2014–15 (from 24.4%).
3.2.1 Profile of current tobacco use 
Males (20.6%) were more likely than females (14.3%) to smoke. Smoking levels were highest 
among 25–34-year-olds (28.6%) and lowest among those aged 65 years and older (10.0%) 
(Figure 1). Of those who smoked, 79.9% reported daily smoking and one-quarter (24.7%) 
smoked at least 20 cigarettes per day (Table 6). Those living in the most deprived quintile 
were more likely to report current smoking, daily smoking, and smoking at least 20 cigarettes 
per day, with 28.3% reporting current smoking compared with 10.2% in the least deprived 




Figure 1 Current tobacco use in Ireland, by sex and age group
3.2.2 Age of first tobacco use
Among survey respondents who reported ever smoking, the mean age of first tobacco use 
was found to be 17.4 years (median: 16 years) and was 16.4 (median: 16 years) for those aged 
15–24 years. There has been an increase in age at first use of tobacco among those aged 
15–24 years across survey time points; in 2002–03, the mean age of first use was 14.6 years 
(median: 15 years), and this has increased with each survey to 16.4 years in 2019–20.
3.2.3 Non-smokers
In 2019–20, more than four-fifths (82.6%) of survey participants were non-smokers; this 
included 57.0% who had never smoked and 25.6% who had stopped using tobacco. Females 
were more likely than males to have never smoked (61.4% versus 52.4%). For both males and 
females, respondents aged 15–24 years were most likely to report never smoking (males: 
73.9%; females: 82.1%). Older adults were more likely to be ex-smokers; 35.7% of respondents 
aged 65 years and older had ceased their tobacco use. More than one-half of ex-smokers 
(57.7%) stated that they had last smoked more than 10 years ago. The main reason given for 
stopping tobacco use was its effects on health or fitness (27.8%). Cost (13.3%) and health 
warnings on tobacco packets (12.7%) were the next most common reasons cited. For 16.4% of 
females, pregnancy or planning to start a family was the second most common reason given 
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Table 4 Main reasons for stopping tobacco use, by sex (%)
Weighted responses=1,463 All Males Females
I think it was affecting my health or fitness 27.8 29.6 25.9
It was costing too much 13.3 15.2 11.3
Health warnings on tobacco packets 12.7 12.7 12.6
I was pregnant or planning to start a family 9.0 2.0 16.4
I was worried it was affecting the health  
of those around me 8.1 8.5 7.7
Family and/or friends asked me to quit 6.5 6.3 6.7
I wanted to get fit 6.4 8.4 4.2
My doctor advised me to give it up 5.9 7.4 4.4
Got sick of them/did not like them anymore 2.9 2.3 3.6
Only occasional/social smoker 1.7 1.5 1.8
Smoking restrictions in public areas 1.4 1.7 1.1
Just gave them up/no reason 1.0 0.9 1.1
Diagnosed with illness 0.9 0.8 0.9
Smoking restrictions in the workplace 0.5 0.5 0.5
Quit.ie website or quit smoking mobile device 
app 0.3 0.5 0.1
Government advertisements on TV 0.2 0.2 0.2
Death/illness of family member 0.2 0.2 0.3
Press or radio advertising for products 0.2 0.1 0.3
Pamphlets or brochures on how to quit 0.0 0.1 0.0
Other 1.0 1.1 1.0
3.2.4 E-cigarette use 
This was the second survey that included questions on e-cigarette use. Lifetime e-cigarette 
use was reported by 14.9% of respondents and current use was reported by 4.3% (Table 
6), which represents a statistically significant increase since 2014–15, when current use was 
found to be 3.1%. Current e-cigarette use was highest among males aged 35–49 years (7.2%) 
and females aged 35–64 years (6.2%) (Table 7), and among those living in the most deprived 
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quintile (7.3%) (Table 8). More than one-half (55.9%) of e-cigarette users were ex-smokers, 
39.6% were current smokers, and 4.5% had never smoked tobacco. The main reason cited 
for starting e-cigarette use was to help quit smoking (59.9%) (Table 5).
Table 5 Main reason for starting e-cigarette use, by sex (%)
Weighted responses=847 All Males Females
To help me quit smoking 59.9 59.6 60.3
To try to cut down on the number of cigarettes 
I smoke 11.9 12.1 11.6
Out of curiosity 10.4 11.6 9.0
To try to stop me going back to smoking 5.1 5.7 4.5
They are cheaper than regular cigarettes 4.3 3.3 5.5
I think they are less harmful than regular 
cigarettes 3.8 3.1 4.5
They seem more acceptable than regular 
cigarettes 1.8 2.1 1.6
I think they taste better than regular cigarettes 1.5 1.2 1.9
You can smoke in places where regular 
cigarettes are banned 0.0 0.1 0.0
Other 1.2 1.3 1.2
3.2.5 Trends in tobacco use
Tobacco use among 15–64-year-olds has reduced with each wave of the NDAS, from 33.2% 
in 2002–03 to 19.5% in 2019–20. In addition, the proportion of never smokers has increased 
with each survey, from 39.9% in 2002–03 to 57.6% in 2019–20 (Figure 2). The 2019–20 survey 
is the first conducted in Ireland where the proportion of ex-smokers was found to be higher 
than the proportion of current smokers. 
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Figure 2 Trends in last month tobacco use among 15–64-year-olds, 2002–03 to 2019–20
3.3 Tables – tobacco use
Table 6 Tobacco use, by sex and age group (%)
All Males Females 15–24 25–34 35–49 50–64 65+
Weighted responses 5,751 2,821 2930 901 902 1,634 1,272 1,033
Current smoker 17.4 20.6 14.3 12.3 28.6 19.0 17.2 10.0
Ex-smoker 25.6 27.0 24.3 9.8 15.1 28.5 32.5 35.7
Never smoker 57.0 52.4 61.4 77.9 56.3 52.5 50.3 54.3
Daily smoking 13.9 15.8 12.2 8.3 21.9 15.6 14.1 9.2
20+ cigarettes  
per day 4.3 5.1 3.4 1.1 4.9 5.0 5.7 3.5
E-cigarettes – 
lifetime use 14.9 16.4 13.4 14.2 21.0 19.5 13.3 5.2
E-cigarettes – 
current use 4.3 4.7 3.8 3.0 3.3 6.7 5.1 1.5
All figures are based on weighted data, are rounded to the nearest decimal place, and are 














2002-03 2006-07 2010-11 2014-15 2019-20
Current smoker 33.2 32.6 28.3 27.4 19.5
Ex-smoker 26.9 25.3 28.3 23.4 22.9
Never smoker 39.9 42.1 43.4 49.2 57.6
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Table 7 Tobacco use, sex by age group (%)
Males (N=2,821) Females (N=2,930)
15–24 25–34 35–49 50–64 65+ 15–24 25–34 35–49 50–64 65+
Current 
smoker 16.3 39.0 20.5 19.2 10.0 8.1 18.5 17.5 15.3 10.0
Ex-smoker 9.8 12.7 29.8 32.8 44.4 9.8 17.4 27.3 32.2 28.0
Never smoker 73.9 48.3 49.7 48.0 45.7 82.1 64.1 55.2 52.5 62.0
Daily smoking 9.3 29.7 16.3 15.1 9.0 7.2 14.4 14.8 13.1 9.4
20+ cigarettes 
per day 1.1 8.1 5.9 6.3 3.4 1.2 1.7 4.1 5.2 3.6
E-cigarettes – 
lifetime use 17.4 24.6 20.7 13.0 5.2 10.8 17.4 18.2 13.5 5.2
E-cigarettes – 
current use 5.6 3.8 7.2 3.9 1.6 0.3 2.8 6.2 6.2 1.3
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
Table 8 Tobacco use by area deprivation quintile (%)
1 (most 
deprived) 2 3 4
5 (least 
deprived)
Weighted responses 1,004 1,364 1,363 1,101 920
Current smoker 28.3 17.7 14.8 16.3 10.2
Ex-smoker 22.8 27.1 26.6 24.8 26.0
Never smoker 48.9 55.2 58.6 58.9 63.8
Daily smoking 24.8 14.7 12.1 11.4 6.6
20+ cigarettes per day 7.6 4.3 3.8 3.5 2.1
E-cigarettes – lifetime use 20.4 15.1 13.2 13.6 12.7
E-cigarettes – current use 7.3 4.0 5.0 3.0 1.7
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.






4.1 Alcohol: main findings
The main findings from the 2019–20 NDAS regarding alcohol use include the following:
•  74.2% of respondents reported having consumed alcohol in the last 12 months (defined as 
current drinking), corresponding to 2,904,000 of the general population in Ireland aged 15 
years and older. 
•  The proportion of the adult population aged 15–64 years who have consumed alcohol in 
the last year has decreased since the 2002–03 survey, from 83.8% to 77.7% in 2019–20.
•  The median age at which 15–24-year-olds initiated alcohol consumption has increased 
from 16 years to 17 years since 2002–03.
•  One-third (34.1%) of current drinkers typically consume at least 6 standard drinks per 
drinking occasion; this increases to one-half for male drinkers.
•  Two-fifths (39.9%) of drinkers engaged in heavy episodic drinking (HED) at least once per 
month. 
•  The prevalence of alcohol use disorder (AUD) in the general population was found to be 
14.8%, corresponding to one in every seven or 578,000 adults in Ireland.
•  Young males were most likely to have hazardous or harmful drinking patterns. Among male 
drinkers aged 15–24 years, 63.1% engaged in monthly HED and 37.0% had an AUD.
4.2 Alcohol consumption in Ireland
In the 2019–20 NDAS, 74.2% of survey respondents reported having consumed alcohol in the 
last 12 months (also defined as current drinking), corresponding to 2,903,000 of the general 
population in Ireland aged 15 years and older. There have been no significant changes in 
the prevalence of alcohol consumption since 2014–15. This section provides an overview 
of general patterns of consumption, harmful patterns of consumption, trends in alcohol 
consumption, and harms arising from alcohol use. More detailed tables on general patterns 
of alcohol consumption as well as on hazardous and harmful drinking patterns may be found 
at the end of this chapter. For the purposes of this survey, a standard drink contains 10 g of 
pure alcohol. This is the equivalent of one glass (or half a pint) of beer, or a pub measure of 
spirits (35.5 mL), or a small (100 mL) glass of wine.
4.2.1 Non-drinkers
One-quarter of respondents (25.7%) did not consume alcohol in the 12 months prior to 
the NDAS (defined as non-drinkers). Females (28.4%) were more likely than males (23.1%) 
to be non-drinkers (Table 10, Figure 3). The highest proportion of non-drinkers was in the 
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65 years and older age group (45.2% of females and 36.6% of males) (Table 11), followed by 
the 15–24-year-old age group (28.2%). The proportion of non-drinkers varied by level of 
deprivation – 30.0% of those in the most deprived quintile were non-drinkers, compared 
with 21.4% in the least deprived quintile (Table 12).  
Figure 3 Proportion of non-drinkers in the year prior to the 2019–20 NDAS, by age and sex
The proportion of ex-drinkers was found to be 6.1%, corresponding to 240,000 of the 
general population (Table 10). The most common reason given for stopping alcohol use was 
health reasons (28.4%). Males also reported lifestyle reasons (19.5%) and not enjoying drinking 
or getting drunk (15.4%), while females also reported not enjoying drinking or getting drunk 
(25.3%) and being pregnant and/or breastfeeding (18.6%) as the most common reasons they 
stopped drinking (Table 9).
Table 9 Main reason for stopping alcohol use, by sex (%)
Weighted responses=350 All Males Females
Health reasons (e.g. weight, diabetes, avoiding 
hangovers) 28.4 31.4 25.7
Taste/enjoyment (e.g. I did not enjoy drinking/
getting drunk) 20.6 15.4 25.3
Lifestyle reasons (e.g. work/study commitments, 
less opportunity, young family) 14.0 19.5 9.0
Pregnant and/or breastfeeding 9.8 0.0 18.6
Social reasons (e.g. believe in moderation, 
concerned about violence, avoiding getting drunk) 5.4 5.3 5.5


























Weighted responses=350 All Males Females
Drink driving regulations 2.9 4.4 1.5
Financial reasons 2.8 3.8 1.9
Family and/or friends asked me to give up drinking 1.5 2.4 0.7
The price of the alcohol I drank increased 0.5 0.7 0.3
Other 9.9 10.9 9.1
4.2.1.1 Trends in the proportion of the population that does not drink
There has been a decrease in the proportion of current drinkers aged 15–64 years in the 
general population – from 83.8% in 2002–03 to 77.7% in 2019–20. This can be explained by 
an increase in the proportion of never drinkers rather than an increase in the number of 
people quitting their alcohol use (Figure 4). The largest increases in never drinkers have been 
observed in the 15–24-year-old and 25–34-year-old age groups (Table 13).
 
















2002-03 2006-07 2010-11 2014-15 2019-20
Current drinker 83.8 84.2 85.3 79.9 77.7
Ex-drinker 6.4 6.2 5.0 5.3 5.3
Never drinker 9.8 9.7 9.7 14.8 17.0
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4.2.2 Age of first use of alcohol
Among survey participants who had used alcohol, the mean age of first use was found to be 
17.7 years (median: 17 years). There has also been an increase in the age of first use of alcohol 
among those aged 15–24 years; in 2002–03, the mean age of first use was 15.6 years (median: 
16 years), and this increased with each survey to 16.6 years (median: 17 years) in 2019–20.
4.3 General patterns of alcohol consumption
4.3.1 Frequency of drinking in the last year
More than one-half of drinkers (56.8%) reported drinking alcohol at least once per week 
(Figure 5). Males consumed alcohol more frequently than females, with 63.1% of males 
consuming alcohol weekly compared with 50.3% of females. Older drinkers reported drinking 
more frequently than those in younger age groups; 13.6% of drinkers aged 65 years and older 
consumed alcohol at least four times per week, compared with just 1.5% of drinkers aged 
15–24 years (Table 10).  
 

























4.3.2 Quantity of alcohol consumed per typical drinking 
occasion
The mean number of standard drinks consumed per typical drinking occasion was 5.0. This 
ranged from 3.8 among females to 6.2 among males and from 6.1 among 15–24-year-olds 
to 3.6 among those aged 65 years and older. One-third (34.1%) of respondents reported 
drinking at least six standard drinks per typical drinking occasion over the last year (Figure 
6). While young people drank less frequently than those in older age groups, they consumed 
more alcohol per typical drinking occasion, with 45.5% of 15–24-year-olds and 45.6% of 
25–34-year-olds consuming at least six standard drinks per drinking occasion. This level 
of consumption was almost twice as common among 15–24-year-old males (58.4%) than 
15–24-year-old females (31.3%). A similar trend was observed among 25–34-year-olds, with 
61.3% of males and 28.4% of females consuming alcohol in this way. One-fifth (19.5%) of 
males reported consuming 10 or more drinks per typical drinking occasion compared with 
just 3.3% of females (Table 10). Drinkers were also asked the highest number of standard 
drinks they had consumed on a single occasion in the last year; 8.3% reported consuming at 
least 20 drinks on a single occasion (Table 10). 
 
Figure 6 Proportion of drinkers who consumed at least six standard drinks on a typical drinking 
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4.4 Hazardous and harmful drinking patterns 
in Ireland
Three internationally agreed methods to measure hazardous or harmful drinking patterns are 
included in the current NDAS:
•  Heavy episodic drinking (HED) is defined as consuming six or more standard drinks on a 
single occasion at least once per month in the last year. Engaging in monthly HED may be 
considered a hazardous pattern of drinking.5 
•  The World Health Organization’s Alcohol Use Disorders Identification Test–Concise 
(AUDIT-C) is a three-question screening test that asks about frequency of drinking, typical 
volume consumed per drinking occasion, and HED. In this survey, a score of 5 or higher is 
considered positive for a hazardous pattern of drinking.6
•  AUD is measured using the Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM-5).7 An AUD diagnosis requires meeting at least 2 of the following 11 criteria 
in the last year: role impairment; hazardous use; social problems; tolerance; withdrawal; 
longer or more use than intended; unsuccessful attempts to quit/cut down; much time 
spent using alcohol; reduced activities because of drinking; continued drinking despite 
psychological or physical problems; and alcohol cravings. AUD severity levels were 
classified as mild, moderate, or severe (2–3, 4–5, or ≥6 criteria, respectively). 
4.4.1 Heavy episodic drinking
Two-fifths (39.9%) of drinkers engaged in monthly HED in the year prior to the survey, and 
almost one-quarter (23.7%) engaged in HED on a weekly basis (Table 10). Monthly HED 
was more prevalent among male than female drinkers (53.0% versus 26.4%) and among 
15–24-year-old drinkers than among those aged 65 years and older (56.4% versus 25.7%). 
Overall, monthly HED was most prevalent among 15–24-year-old male drinkers (63.1%) and 
was also common among 15–24-year-old female drinkers (49.0%) (Figure 7). Although those 
aged 65 years and older were the least likely to engage in monthly HED, two-fifths of male 
drinkers (40.3%) in this age group reported monthly HED. Monthly HED was more common 
among drinkers living in the most deprived quintile (45.4%) compared with those living in less 
deprived quintiles (Table 12).
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Figure 7 Proportion of drinkers who engaged in monthly HED, sex by age group
4.4.1.1 Trends in heavy episodic drinking
Although the current level of monthly HED in Ireland is high by international standards,5 there 
has been a decrease in the proportion of drinkers aged 15–64 years reporting monthly HED, 
which peaked in 2006 (58.6%) and decreased in each subsequent survey to 42.3% in the 
current survey (Table 14). This coincides with a decrease in per capita alcohol consumption in 
Ireland since the early to mid-2000s. In 2006, per capita alcohol consumption was 13.4 L of 
pure alcohol per adult aged 15 years and older, but by 2019 this had decreased to 10.8 L. The 
largest decline in monthly HED was observed among 15–24-year-olds, from 73.7% in 2002–03 
to 56.4% in 2019–20 (Figure 8).
 









































2002-03 2006-07 2010-11 2014-15 2019-20
15–24 73.7 71.6 64.6 57.0 56.4
25–34 57.4 69.0 58.8 57.7 46.0
35–49 37.8 53.0 48.6 39.8 37.7
50–64 27.2 40.4 40.6 37.1 36.2
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4.4.2 AUDIT-C
More than one-half (51.3%) of all drinkers were classified as hazardous drinkers using the 
World Health Organization’s AUDIT-C screening tool (Table 10). This was more common 
among male (65.7%) than female drinkers (36.5%), particularly younger males, with 70.4% of 
15–24-year-old male drinkers meeting the criteria for hazardous drinking (Table 11, Figure 9). 
Drinkers aged 65 years and older were least likely to have an AUDIT-C score of 5 or higher 
(38.2%). An AUDIT-C score of 5 or higher was most common among drinkers living in the 
most deprived quintile (58.5%) (Table 12).
 
Figure 9 Proportion of drinkers with an AUDIT-C score of 5 or higher, sex by age group
4.4.2.1 Trends in AUDIT-C scores
AUDIT-C scores are also available for the 2010–11 and 2014–15 surveys. The proportion of 
drinkers aged 15–64 years with an AUDIT-C score of 5 or higher increased from 57.6% to 
60.1% between 2010–11 and 2014–15, and decreased to 53.5% in the current survey. The 



























Figure 10 Trends in proportion of drinkers (aged 15–64 years) with an AUDIT-C score of 5 or 
higher, by age group
 
4.4.3 Alcohol use disorder
This is the first NDAS to measure AUD using DSM-5 criteria. The prevalence of last-year AUD 
in the general population was found to be 14.8%, corresponding to 578,000 of the general 
population in Ireland aged 15 years and older. This equates to one in five drinkers (20.0%). 
The proportion of drinkers with mild, moderate, and severe AUD was 11.6%, 5.4%, and 3.1%, 
respectively (Table 10). AUD was more common among male than female drinkers (24.8% 
versus 15.1%). Younger drinkers aged 15–24 years were most likely to report AUD (37.5%), 
whereas drinkers aged 65 years and older were least likely to report AUD (6.7%).
The highest prevalence of AUD was observed among female drinkers aged 15–24 years 
(38.0%), followed by male drinkers aged 25–34 years (37.1%) and male drinkers aged 15–24 
years (37.0%) (Figure 11). The high prevalence among young female drinkers is somewhat 
surprising, given that males aged 15–24 years were much more likely to report monthly HED 
and to have an AUDIT-C score of 5 or higher. Similarly, 15–24-year-old females were more 
likely to report mild AUD (21.6%) than 15–24-year-old or 25–34-year-old males (15.0% and 
14.6%, respectively) (Table 11). There were no significant differences in the prevalence of AUD 
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Figure 11 Proportion of drinkers with AUD, sex by age group
4.5 Self-perception of own drinking
Drinkers were asked to classify themselves as one of the following types of drinkers:
• Light drinker
• Light drinker who sometimes binge drinks
• Moderate drinker 
• Moderate drinker who sometimes binge drinks
• Heavy drinker, or
• Heavy drinker who sometimes binge drinks.
The majority of drinkers (74.1%) classified themselves as either a light or moderate drinker 
(Figure 12). A further one-quarter (24.1%) of drinkers classified themselves as a light drinker 
who sometimes binge drinks or a moderate drinker who sometimes binge drinks, and 1.7% 
classified themselves as either a heavy drinker or as a heavy drinker who sometimes binge 
drinks. Among those with AUD, just 7.0% classified themselves as a heavy drinker, whereas 




























Figure 12 Drinkers’ self-reported drinker type, by drinking pattern 
4.6 Alcohol-related harm
The current survey contained questions relating to both harms arising from a drinker’s own 
alcohol consumption and harms due to others’ drinking.
4.6.1 Harm from own drinking
Drinkers were asked if they had experienced any of the following negative consequences as a 
result of their own drinking in the last year: role impairment (for example, at work, at school, 
or when taking care of the household), accidentally hurt yourself, been in a fight, harm to 
home life or marriage, and harm to health. The proportion of drinkers who reported at least 
one of these harms was 13.5%, ranging from 3.1% who experienced harm to their home life 
or marriage to 10.2% who had accidentally hurt themselves (Table 16). Males were more likely 
than females to experience any harm (17.3% versus 9.8%) and those aged 15–24 years were 
most likely to experience harm (27.6%). 
Experiencing harm was associated with drinking pattern. Low-risk drinkers (defined as 
those who did not engage in regular HED or meet the criteria for AUD) were least likely to 
experience any harm (5.2%), while those with AUD were 13 times more likely to experience 
harm (67.1%) (Figure 13, Table 18).
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Figure 13 Harms from own alcohol consumption in the year prior to the survey, by drinking 
pattern
4.6.2 Harm from others’ drinking
All respondents were asked if there were people in their life (family, friends, co-workers, or 
others) that they would consider to be a fairly heavy drinker or someone who drinks a lot 
sometimes, and whether this affected them. One-third (33.0%) reported that there were 
such people in their life and 13.8% of all respondents reported that they were affected 
because of this.
All respondents were also asked if they had experienced any of the following negative 
consequences as a result of others’ drinking in the last year: harm to family, been a passenger 
with a drunk driver, been assaulted, financial harm, and having property vandalised. Harm 
from others’ drinking was experienced by 17.0% of all respondents, with 18.3% of males and 
15.7% of females reporting such harm (Table 16). The most commonly reported harm was 
harm to family (10.8%), followed by being a passenger with a drunk driver (6.0%). Females 
were more likely than males to report harm to family (13.1% versus 8.5%) and to report 
financial harm (2.9% versus 2.4%). Similar proportions of non-drinkers (11.8%) and low-risk 
drinkers (13.1%) reported harms from others’ drinking (Figure 14, Table 19). In comparison, 
23.7% of monthly HED drinkers and 43.4% of those with AUD reported harm from others’ 
drinking. Low-risk drinkers were more than twice as likely to report harm from someone 
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Figure 14 Harms from others’ alcohol consumption in the year prior to the survey, by drinking 
pattern
4.7 Alcohol tables
Table 10 Drinking patterns, by sex and age group (%)
Drinking status (all) (N=5,762)
All Males Females 15–24 25–34 35–49 50–64 65+
Never drinker 19.6 17.2 22.0 26.4 13.0 12.6 18.7 31.5
Ex-drinker 6.1 5.9 6.4 1.8 5.7 5.3 7.7 9.7
Current drinker 74.2 76.9 71.6 71.8 81.3 82.1 73.6 58.8
Frequency of drinking (drinkers only) (N=4,277)
All Males Females 15–24 25–34 35–49 50–64 65+
Less than monthly 16.8 14.1 19.5 16.1 18.5 15.5 14.3 21.8
1–3 times per month 26.4 22.7 30.2 35.0 31.7 27.1 21.7 16.5
1–3 times per week 51.0 55.8 46.0 47.4 46.7 52.5 56.6 48.1
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Number of standard drinks consumed on a typical drinking occasion (drinkers only)
All Males Females 15–24 25–34 35–49 50–64 65+
1–2 drinks 25.5 16.3 34.8 12.4 17.4 26.7 27.2 43.2
3–5 drinks 40.5 33.6 47.5 42.1 37.0 41.0 42.8 38.1
6–9 drinks 22.6 30.6 14.3 27.6 28.8 21.7 20.7 14.7
10+ drinks 11.5 19.5 3.3 17.9 16.8 10.7 9.3 4.0
Mean 5.0 6.2 3.8 6.1 6.0 4.9 4.7 3.6
Highest number of standard drinks consumed on a single occasion in the last year 
(drinkers only)
All Males Females 15–24 25–34 35–49 50–64 65+
1–5 drinks 33.1 20.5 45.9 20.1 19.9 27.6 40.4 61.5
6–9 drinks 29.1 23.9 34.5 30.1 29.9 31.6 28.9 22.3
10–19 drinks 29.5 40.9 17.8 35.6 37.9 32.3 25.0 14.6
20+ drinks 8.3 14.8 1.8 14.4 12.3 8.5 5.8 1.6
Frequency of HED among drinkers
All Males Females 15–24 25–34 35–49 50–64 65+
Never 27.5 17.9 37.4 15.7 16.5 22.9 33.9 53.3
Less than monthly 32.6 29.1 36.2 27.9 37.5 39.4 29.9 21.0
1–3 times per month 16.3 19.3 13.1 23.1 21.5 16.0 13.8 6.9
Weekly 23.7 33.7 13.3 33.4 24.5 21.7 22.4 18.8
Hazardous drinking among those who drank in the last year (drinkers only)
All Males Females 15–24 25–34 35–49 50–64 65+
Monthly HED 39.9 53.0 26.4 56.4 46.0 37.7 36.2 25.7
AUDIT-C  
score of 5+ 51.3 65.7 36.5 64.2 57.1 50.4 48.0 38.2
Prevalence of AUD
AUD (all) 14.8 19.1 10.8 26.9 22.8 16.2 7.7 3.9
AUD (drinkers only) 20.0 24.8 15.1 37.5 28.1 19.7 10.5 6.7
Mild AUD 11.6 13.0 10.1 18.1 14.5 12.8 7.2 4.8
Moderate AUD 5.4 7.6 3.1 11.2 9.2 4.7 1.8 1.6
Severe AUD 3.1 4.2 1.9 8.2 4.4 2.2 1.5 0.3
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
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Table 11 Drinking patterns, sex by age group (%)
Drinking status (all) (N=5,762)
Males Females
15–24 25–34 35–49 50–64 65+ 15–24 25–34 35–49 50–64 65+
Never drinker 23.3 9.3 12.8 17.6 25.1 29.6 16.7 12.3 19.7 37.2
Ex-drinker 1.7 3.7 5.3 6.7 11.5 1.9 7.6 5.4 8.7 8.1
Current drinker 75.0 87.0 81.9 75.7 63.4 68.5 75.8 82.4 71.6 54.8
Frequency of drinking (drinkers only) (N=4,277)
15–24 25–34 35–49 50–64 65+ 15–24 25–34 35–49 50–64 65+
Less than 
monthly 16.7 15.0 12.0 14.2 14.7 15.4 22.4 18.9 14.4 29.1
1–3 times  
per month 27.1 24.4 24.7 20.9 14.3 43.8 39.9 29.4 22.5 18.7
1–3 times  
per week 55.2 57.1 55.4 57.5 53.2 38.6 35.1 49.7 55.7 43.0
4+ times  
per week 0.9 3.5 7.9 7.4 17.9 2.2 2.6 2.0 7.4 9.3
Number of standard drinks consumed on a typical drinking occasion (drinkers only)
15–24 25–34 35–49 50–64 65+ 15–24 25–34 35–49 50–64 65+
1–2 drinks 8.4 10.5 19.1 15.1 28.1 16.8 25.0 34.0 39.3 58.9
3–5 drinks 33.2 28.2 31.9 37.3 38.6 51.9 46.7 49.9 48.4 37.6
6–9 drinks 32.0 33.5 29.9 31.4 25.8 22.8 23.7 13.7 9.9 3.3
10+ drinks 26.4 27.8 19.1 16.2 7.6 8.5 4.7 2.4 2.4 0.3
Mean 7.0 7.4 6.2 5.9 4.6 5.1 4.4 3.7 3.4 2.6
Highest number of standard drinks consumed on a single occasion in the last year  
(drinkers only)
15–24 25–34 35–49 50–64 65+ 15–24 25–34 35–49 50–64 65+
1–5 drinks 12.5 12.1 15.9 23.4 43.2 28.5 28.2 38.7 57.5 80.3
6–9 drinks 23.8 18.7 22.7 26.6 28.4 37.1 42.0 40.1 31.3 16.0
10–19 drinks 43.9 46.6 44.5 39.9 25.3 26.2 28.6 20.7 9.8 3.7
20+ drinks 19.8 22.6 16.9 10.1 3.1 8.3 1.2 0.5 1.4 0.1
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Frequency of HED among drinkers
Males Females
15–24 25–34 35–49 50–64 65+ 15–24 25–34 35–49 50–64 65+
Never 11.5 10.5 12.9 22.4 38.0 20.4 23.1 32.7 45.7 68.8
Less than 
monthly 25.4 30.4 34.3 28.4 21.7 30.6 45.3 44.4 31.5 20.3
1–3 times per 
month 24.2 22.5 20.3 17.3 10.6 21.8 20.5 11.8 10.2 3.3
Weekly 38.9 36.7 32.5 31.9 29.7 27.2 11.1 11.2 12.5 7.7
Hazardous drinking among those who drank in the last year (drinkers only)
15–24 25–34 35–49 50–64 65+ 15–24 25–34 35–49 50–64 65+
Monthly HED 63.1 59.1 52.8 49.2 40.3 49.0 31.6 23.0 22.8 11.0
AUDIT-C  
score of 5+ 70.4 69.4 66.9 63.5 56.5 57.3 43.6 34.3 32.3 19.2
Prevalence of AUD
AUD (all) 27.8 32.2 21.5 10.3 6.1 26.1 13.7 11.1 5.3 2.0
AUD (drinkers 
only) 37.0 37.1 26.2 13.6 9.7 38.0 18.1 13.4 7.3 3.7
Mild 15.0 14.6 16.1 9.4 7.3 21.6 14.3 9.7 5.0 2.2
Moderate 14.1 15.3 6.5 1.9 1.9 7.9 2.4 2.9 1.8 1.3
Severe 7.9 7.1 3.7 2.3 0.4 8.6 1.4 0.8 0.6 0.2
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
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Table 12 Drinking patterns, by area deprivation quintile (%)
Drinking status (all) (N=5,762)
1 (most 
deprived) 2 3 4
5 (least 
deprived)
Never drinker 21.2 23.4 19.0 16.0 17.7
Ex-drinker 8.8 6.7 6.0 5.3 3.7
Current drinker 70.0 70.0 74.9 78.7 78.6
Frequency of drinking (drinkers only) (N=4,277)
1 2 3 4 5
Less than monthly 19.6 18.7 18.2 15.0 11.6
1–3 times per month 25.3 28.6 26.3 24.4 27.2
1–3 times per week 51.6 47.3 51.5 53.3 51.7
4+ times per week 3.6 5.4 4.1 7.2 9.5
Number of standard drinks consumed on a typical drinking occasion (drinkers only)
1 2 3 4 5
1–2 drinks 17.4 20.4 25.6 30.7 33.5
3–5 drinks 38.5 41.3 41.7 37.6 42.8
6–9 drinks 27.4 24.2 22.2 21.4 17.7
10+ drinks 16.7 14.1 10.6 10.3 6.0
Mean 6.0 5.5 4.9 4.7 4.1
Highest number of standard drinks consumed on a single occasion in the last year 
(drinkers only)
1 2 3 4 5
1–5 drinks 27.8 30.6 34.4 33.7 38.9
6–9 drinks 31.7 30.0 30.8 26.5 26.0
10–19 drinks 30.4 32.1 27.4 30.1 27.4
20+ drinks 10.1 7.3 7.4 9.7 7.7
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Frequency of HED among drinkers
1 2 3 4 5
Never 24.7 25.8 29.9 27.0 29.4
Less than monthly 29.9 33.4 33.8 33.4 31.5
1–3 times per month 16.4 18.1 13.9 15.0 18.5
Weekly 29.1 22.7 22.4 24.5 20.6
Hazardous drinking among those who drank in the last year (drinkers only)
1 2 3 4 5
Monthly HED 45.4 40.8 36.3 39.6 39.1
AUDIT-C score of 5+ 58.5 52.2 48.8 48.6 50.0
Prevalence of AUD
AUD (all) 14.1 13.4 13.4 18.0 16.1
AUD (drinkers only) 20.2 19.2 17.9 22.9 20.5
Mild 11.5 10.8 9.4 13.1 13.8
Moderate 4.3 6.6 5.3 5.8 4.5
Severe 4.4 1.9 3.2 4.0 2.2
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
Table 13 Trends in proportion of non-drinkers (aged 15–64 years), by age and sex
All Males Females 15–24 25–34 35–49 50–64
2002–03 16.2 14.0 18.4 17.7 9.0 15.1 23.6
2006–07 15.8 13.6 18.2 16.8 10.6 14.5 22.7
2010–11 14.7 12.5 16.8 18.3 10.4 13.2 18.6
2014–15 20.5 17.9 23.2 22.7 19.5 17.8 23.6
2019–20 22.3 20.2 24.4 28.2 18.7 17.9 26.4
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Table 14 Trends in proportion of drinkers (aged 15–64 years) reporting monthly HED, by age and sex
All Males Females 15–24 25–34 35–49 50–64
2002–03 48.8 58.4 37.9 73.7 57.4 37.8 27.2
2006–07 58.6 69.1 46.2 71.6 69.0 53.0 40.4
2010–11 52.3 63.8 40.3 64.6 58.8 48.6 40.6
2014–15 46.8 60.9 31.9 57.0 57.7 39.8 37.1
2019–20 42.3 55.1 29.0 56.4 46.0 37.7 36.2
Table 15 Trends in proportion of drinkers (aged 15–64 years) with a positive AUDIT-C score, by age 
and sex
All Males Females 15–24 25–34 35–49 50–64
2010–11 57.6 70.3 44.3 66.1 62.7 55.1 48.6
2014–15 60.1 75.4 43.8 67.9 67.7 55.2 52.7
2019–20 53.5 67.2 39.5 64.2 57.1 50.4 48.0
Table 16 Harms from alcohol consumption in the year prior to the survey, by sex and age group
All Males Females 15–24 25–34 35–49 50–64 65+
Harms in the last year from own drinking (drinkers only) N=4,277
Role impairment 5.9 8.4 3.3 14.6 9.2 5.3 1.5 0.6
Accidentally hurt 
yourself 10.2 12.0 8.4 25.7 13.9 7.5 4.6 3.9
Been in a fight 3.2 4.3 2.1 11.9 5.0 1.1 0.6 0.3
Harm to home life/
marriage 3.1 4.5 1.7 4.2 3.2 4.4 2.0 0.8
Harm to health 8.0 10.7 5.2 15.9 8.7 7.8 5.5 3.1
1+ harm 13.5 17.3 9.8 27.6 19.4 13.6 7.4 3.5
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Harms in the last year from others’ drinking (all respondents) N=5,762
All Males Females 15–24 25–34 35–49 50–64 65+
Harm to family 10.8 8.5 13.1 11.0 15.6 12.5 9.4 5.5
Been a passenger 
with a drunk driver 6.0 8.5 3.6 11.5 8.9 5.5 3.3 2.6
Assaulted 4.5 6.4 2.7 12.6 6.2 3.8 1.6 0.6
Financial harm 2.7 2.4 2.9 3.1 3.7 3.6 1.6 1.1
Property vandalised 4.0 4.7 3.3 8.9 7.1 3.8 1.1 0.7
1+ harm 17.0 18.3 15.7 24.0 23.9 18.8 12.5 7.5
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
Table 17 Harms from alcohol consumption in the year prior to the survey, sex by age group
Males Females
15–24 25–34 35–49 50–64 65+ 15–24 25–34 35–49 50–64 65+
Harms in the last year from own drinking (drinkers only) N=4,277
Role 
impairment 18.1 14.6 8.1 1.8 0.5 10.9 3.1 2.5 1.1 0.7
Accidentally 
hurt yourself 23.5 16.9 10.7 6.1 4.7 28.2 10.6 4.4 3.0 3.1
Been in a fight 15.6 7.1 1.4 0.4 0.0 7.9 2.6 0.7 0.7 0.5
Harm to home 
life/marriage 3.6 5.6 7.1 2.8 1.3 4.9 0.6 1.8 1.1 0.3
Harm to health 17.2 14.1 10.9 6.8 5.0 14.4 2.8 4.7 4.2 1.1
1+ harm 29.5 26.4 18.7 9.6 5.3 25.7 12.6 8.6 5.3 2.0
Harms in the last year from others’ drinking (all respondents) N=5,762
15–24 25–34 35–49 50–64 65+ 15–24 25–34 35–49 50–64 65+








15–24 25–34 35–49 50–64 65+ 15–24 25–34 35–49 50–64 65+
Assaulted 15.9 10.1 4.9 3.0 0.8 9.2 2.4 2.8 0.2 0.4
Financial harm 2.1 3.1 3.7 1.5 1.3 4.2 4.3 3.5 1.7 1.0
Property 
vandalised 10.3 10.1 3.4 1.4 0.6 7.5 4.2 4.2 0.8 0.7
1+ harm 25.7 28.8 18.3 13.0 8.4 22.2 19.2 19.3 12.1 6.8
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses. 
Table 18 Harms from own alcohol consumption in the year prior to the survey, by drinking pattern
No monthly 
HED or AUD Monthly HED Any AUD
Role impairment 0.7 10.3 26.3
Accidentally hurt yourself 2.8 16.6 39.2
Been in a fight 1.1 5.3 11.7
Harm to home life/marriage 0.6 4.8 13.1
Harm to health 1.3 14.3 33.1
1+ harm 5.2 29.0 67.1




HED or AUD Monthly HED Any AUD
Harm to family 9.4 9.4 11.6 22.6
Been a passenger with  
a drunk driver 2.4 3.1 11.9 21.7
Assaulted 3.2 1.7 8.3 17.2
Financial harm 2.4 1.9 3.2 6.9
Property vandalised 2.2 2.0 6.7 14.2
1+ harm 11.8 13.1 23.7 43.4







This chapter presents data on the use of illegal drugs. In this survey, ‘any illegal drug’ refers 
to cannabis, ecstasy, cocaine powder, magic mushrooms, amphetamines, poppers, LSD, new 
psychoactive substances (NPS), solvents, crack, and heroin. It should be noted that poppers 
and solvents are not illegal in Ireland. However, they are included here to ensure consistency 
with previous surveys. Three recall periods are used to measure drug use prevalence:
•  Lifetime prevalence refers to the proportion of the sample that reported ever having 
used the named drug at the time they were surveyed. 
•  Last year prevalence refers to the proportion of the sample that reported using a 
named drug in the year prior to the survey. Last year prevalence is often referred to as 
recent use. 
•  Last month prevalence refers to the proportion of the sample that reported using a 
named drug in the 30-day period prior to the survey. Last month prevalence may also be 
referred to as current use.
This chapter contains the main findings on last year (recent) illegal drug use. More detailed 
tables on lifetime, last year, and last month prevalence, by sex and age group, and including 
95% confidence intervals for each drug, are provided in Appendix I. Tables on trends in 
lifetime, last year, and last month prevalence of each drug, including significance testing, are 
provided in Appendix II. It should be noted that the survey methodology changed in 2014–15 
to include all adults aged 15 years and older (for the first three surveys, the study population 
only included those aged 15–64 years). To analyse trends across all five surveys, only those 
aged 15–64 years were included in these analyses.
5.1 Illegal drug use: Main findings
The main findings from the 2019–20 NDAS regarding illegal drug use include the following:
•  23.0% of respondents reported lifetime use of any illegal drug, corresponding to 899,000 
adults aged 15 years and older in the general population in Ireland; 7.4% (corresponding 
to 289,000 adults in the general population) reported recent or last year use; and 4.1% 
(corresponding to 161,000 adults in the general population) reported current or last month 
use.
• The most commonly used illegal drugs in the 12 months prior to the survey were: 
 1.  Cannabis (5.9%)
 2.  Ecstasy (2.2%)
 3.  Cocaine (1.9%)
 4.  Poppers (1.4%)
 5.  LSD (0.9%) 
 6.  Amphetamines (0.8%) 
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• Males were more likely than females to report recent illegal drug use (10.2% versus 4.7%). 
• Young people aged 15–24 years were most likely to report recent illegal drug use (18.5%). 
• Males aged 25–34 years had the highest reported level of recent illegal drug use (25.8%).
•  An increase in recent illegal drug use since 2014–15 was reported for several illegal drugs, 
including cocaine, ecstasy, LSD, amphetamines, and poppers. A small decrease in recent 
use of cannabis was reported.
•  Those who used drugs were more likely to report recent use of at least three different 
drugs in 2019–20 (25.0%) compared with 2014–15 (15.4%).
5.2 How many people use illegal drugs and 
how has this changed?
In 2019–20, 23.0% of survey participants aged 15 years and older reported use of an illegal 
drug at some point in their lifetime, corresponding to 899,000 adults aged 15 years and older 
in the general population in Ireland; 7.4% (corresponding to 289,000 adults in the general 
population) reported last year or recent use; and 4.1% (corresponding to 161,000 adults in 
the general population) reported last month or current use. For adults aged 15–64 years, the 
equivalent prevalence rates were 27.1% for lifetime use, 9.0% for last year use, and 4.9% for 
last month use. 
Although the prevalence of recent illegal drug use among survey participants aged 15 years 
and older was similar in 2019–20 (7.4%) and 2014–15 (7.3%), a statistically significant increase 
in recent use since 2014–15 was reported for cocaine, LSD, amphetamines, and poppers. A 
non-significant decrease in recent use of cannabis was also reported (from 6.5% in 2014–15 

















5.2.1 Number of drugs used
Although the prevalence of recent drug use has remained stable since the 2014–15 survey, 
the 2019–20 NDAS found that those who reported recent illegal drug use were more likely to 
report use of at least two illegal drugs. In 2019–20, one-quarter of those who reported illegal 
drug use reported use of at least three illegal drugs, compared with 15.4% in 2014–15 (Figure 
15). 
Figure 15 Number of illegal drugs used by those reporting recent use of illegal drugs in 2014–15 
and 2019–20
5.3 Drug use by age group and sex
Males were more than twice as likely as females to report recent use of an illegal drug (10.2% 
versus 4.7%). The youngest age group (15–24 years) had the highest prevalence of drug use 
(18.5%), with little difference between males and females (Figure 16). There were considerable 
differences among male and female 25–34-year-olds, with males in this age group being 
three times more likely than females to report recent drug use (25.8% versus 8.4%). Males 
aged 25–34 years had the highest prevalence of recent drug use (25.8%). Those aged 35–64 
years reported a relatively low prevalence of drug use (3.5%), with males in this age group 
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Figure 16 Recent use of any illegal drug, by sex and age group
 
For all illegal drugs except for cocaine and NPS, recent use was most common among 
15–24-year-olds (Figure 17).
Figure 17 Recent use of illegal drugs, by drug type and age group
5.3.1 Trends in recent use of illegal drugs among 15–64-year-
olds
Although illegal drug use increased steadily between 2002–03 and 2014–15, no significant 
increase in the proportion of 15–64-year-olds reporting use of any illegal drug use was 
observed in the 2019–20 NDAS compared with the 2014–15 survey (Figure 18).





























































Figure 18 Trends in recent use of any illegal drug among 15–64-year-olds, by sex
 
Since 2002–03, there has been a steady increase in each survey in the proportion of males 
aged 25–34 years who reported recent illegal drug use (from 9.1% in 2002–03 to 25.8% in 
2019–20). Among males aged 15–24 years, recent illegal drug use increased from 17.1% in 
2002–03 to 25.4% in 2014–15, but decreased to 20.6% in 2019–20 (Figure 19). While females 
were much less likely to use illegal drugs, the prevalence of illegal drug use among females 
aged 15–24 years and 25–34 years has doubled since 2002–03. The prevalence of illegal drug 
use among 35–64-year-olds has been fairly stable since 2006–07 for both males and females.
 








































15-24 25-34 Males 35–64 15-24
25-34 
Females 35-64
2002-03 17.1 9.1 2.9 8.2 4.2 0.8
2006-07 20.2 11.7 4.2 10.2 6.7 1.5
2010-11 24.4 17.6 5.2 11.4 5.6 1.3
2014-15 25.4 20.3 5.5 12.0 6.7 1.7
2019-20 20.6 25.8 5.4 16.3 8.4 1.6
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5.4 Age at which people start using illegal drugs 
The median age at first use of the most commonly used illegal drugs was higher in 2019–20 
when compared with the 2002–03 survey, except for poppers. The median age at first use of 
each drug was found to be similar in 2019–20, ranging from 19 years for cannabis and poppers 
to 21 years for cocaine (Table 20). 





Cannabis 19.2 (18) 19.7 (19)
Ecstasy 19.4 (18) 19.9 (20)
Cocaine 21.5 (20) 21.9 (21)
Poppers 20.2 (19) 20.1 (19)
LSD 18.4 (18) 20.6 (20)
Amphetamines 19.9 (19) 20.7 (20)
5.5 Illegal drug use by area deprivation level
There were differences in recent drug use according to area deprivation level (Figure 20). 
Those living in the fourth least deprived quintile reported the highest rate of drug use (9.6%) 
while those in the third least deprived reported the lowest (5.4%). Similar rates of drug use 
were reported by the most (8.4%) and least (8.3%) deprived areas.
 

























The 2019–20 survey contained new questions on polydrug use, which was defined as the 
use of at least two drugs on the same occasion (simultaneously) in the last year. Table 21 
presents the drugs that were used in addition to cannabis, cocaine, and ecstasy. Alcohol was 
the substance most commonly used with cannabis, cocaine, and ecstasy; 29.8% of recent 
cannabis users did not use any additional substances with cannabis at any time in the last 
year, compared with 4.5% of recent cocaine users. 







None 29.8 4.5 13.0
Alcohol 68.1 93.4 86.0
Cannabis – 22.3 5.0
Cocaine 7.3 – 6.6
Ecstasy 4.9 9.2 –
LSD 2.5 0.0 0.0
Poppers 2.3 2.6 0.0
Amphetamines 2.2 0.0 0.0
Magic mushrooms 2.2 0.0 0.9
Opioid pain relievers 1.7 0.0 0.5
Sedatives or tranquillisers 0.7 0.0 0.0
5.7 Factors associated with using drugs
This section presents recent illegal drug use in relation to a number of socioeconomic 
and demographic variables. These were education, employment, marital status, housing, 
and region of residence. Results are also presented for 15–34-year-olds, as drug use is 
most prevalent in this age group (Table 22). For those aged 15–34 years, the prevalence of 
recent drug use was higher among those who had only completed lower secondary school 
education (30.7%) compared with those with higher educational attainment or who were still 
in education. There was little difference in prevalence between 15–34-year-olds who were 
employed (18.7%), unemployed (20.8%), or students (17.2%). Single 15–34-year-olds had a 
higher prevalence of recent drug use (21.2%) compared with those who were married (9.3%). 
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Those aged 15–34 years living in rented accommodation (21.0%) or with their parents/family 
(19.9%) were more likely to report recent drug use than those who owned their own housing 
(11.1%). Respondents aged 15–34 years who lived in Dublin had the highest prevalence of 
recent drug use (22.9%), while those living in the rest of Leinster had the lowest (13.7%). 










Employed 7.6 18.7 Primary/none 0.7 0.0
Unemployed 14.0 20.8 Lower secondary 3.7 30.7
Student 17.0 17.2 Higher secondary 6.1 18.5
Home duties 2.4 11.5 Third level 6.9 17.1










Owned outright or 
with mortgage 3.3 11.1
 Single/never 
married 16.5 21.2















5.8 Why do some people decide not to use 
drugs?
Respondents who did not report lifetime use of any illegal drug were asked what was the 
main reason that influenced their decision not to use illegal drugs. The most common reason 
respondents gave for not ever using drugs was that they were ‘just not interested’ (39.9%). 
Young respondents were more likely to cite concerns around health problems and becoming 
addicted, whereas older respondents were more likely to cite no opportunity or illegal drugs 
available (Table 23).
Table 23 Reasons why people decide not to use illegal drugs, sex by age group (%)
Weighted responses=4,408 All Males Females
15+ 15–34 35–64 65+ 15–34 35–64 65+
Just not interested 39.9 31.0 40.2 45.8 35.1 41.7 45.5
I think drug taking is wrong 14.1 12.5 13.0 13.5 18.0 13.3 15.1
Worry about health problems 12.8 17.1 14.5 8.1 14.7 11.6 9.3
Did not want to become 
addicted 10.3 15.9 11.3 8.4 10.1 9.2 6.5
No opportunity or  
illegal drugs available 4.6 0.5 4.1 11.3 0.5 4.0 10.3
Did not like to feel out of 
control 3.2 2.4 1.4 2.1 2.3 6.0 3.4
Fear of death 3.0 3.0 1.7 1.1 5.7 3.5 2.1
Family/friends/peer pressure 2.8 5.5 2.8 1.3 4.3 2.1 0.4
Did not think it would be 
enjoyable 2.5 2.3 3.1 2.5 1.8 2.7 2.1
Fear of legal consequences 2.2 2.5 2.2 1.2 3.6 2.1 1.5
Did not want to break the law 1.6 1.4 2.1 1.8 1.3 1.5 1.7









This section contains a more detailed analysis of the three most commonly used illegal drugs 
in Ireland: cannabis, ecstasy, and cocaine. As the prevalence of these drugs is very low among 
those aged 65 years and older, results are predominantly presented for respondents aged 
15–64 years. Tables describing the availability of cannabis, ecstasy, and cocaine are presented 
at the end of this chapter.
6.1 Cannabis: Main findings
The main findings from the 2019–20 NDAS regarding cannabis use include the following:
•  20.7% of respondents had used cannabis in their lifetime, corresponding to 809,000 of 
the general population in Ireland aged 15 years and older. 
•  5.9% of respondents (231,000 of the general population) and 2.9% of respondents 
(113,000 of the general population) had used cannabis in the last year and last month, 
respectively.
•  1.2% of respondents (45,000 of the general population) met the criteria for cannabis use 
disorder. This corresponds to 19.6% of those who reported last year cannabis use.
• The average age of first cannabis use was 19.7 years (median: 19 years). 
•  The average age of participants who reported recent cannabis use was 29.9 years 
(median: 27 years). 
• The average age of first regular cannabis use was 20.6 years (median: 20 years). 
•  The proportion of survey respondents who personally knew somebody who used cannabis 
was 40.3%.
6.1.1 Cannabis use by age group and sex
Recent (last year) use of cannabis was reported by 5.9% of the adult population (7.1% among 
15–64-year-olds) and was higher among males (8.2%) than females (3.6%). Those aged 15–24 
years were most likely to report recent cannabis use (14.5%). There were notable differences 
according to sex in the prevalence of recent cannabis use among those aged 25–34 years, 
with a higher percentage of males reporting recent use (20.6%) compared with females 
(5.7%) in the same age group (Figure 21).
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Figure 21 Recent use of cannabis, by sex and age group
6.1.1.1 Trends in recent cannabis use
Between 2002–03 and 2014–15, recent cannabis use among 15–64-year-olds increased from 
5.0% to 7.7%, and was 7.1% in the current survey. Between 2014–15 and 2019–20, recent 
cannabis use among males decreased from 11.2% to 9.9%, while remaining stable among 
females (Figure 22).
 
Figure 22 Trends in recent use of cannabis among 15–64-year-olds, by sex
Recent cannabis use among males aged 25–34 years increased across each survey, from 











15-24 25-34 35–64 65+
All 14.5 13.1 2.9 0.4
Males 16.3 20.6 4.6 0.2































use among males aged 15–24 years since 2014–15, from 21.5% to 16.3%. Among females aged 
15–24 years, recent use has increased from 6.8% in 2002–03 to 12.8% in 2019–20 (Figure 23).
 
Figure 23 Trends in recent use of cannabis, sex by age group
6.1.2 Frequency of cannabis use
One-fifth (22.7%) of current users used cannabis on 20 days or more in the previous month, 
which is considered to be daily or almost daily use. This was more common among males 
(29.4%) than females (7.5%) and among older (30.5%) than younger (19.8%) respondents 
(Table 24).
Table 24 Frequency of cannabis use in the last month among current users, by sex and age group
 N=159 All Males Females 15–34 35–64
20 days 22.7 29.4 7.5 19.8 30.5
10–19 days 12.3 17.4 0.6 10.9 17.3
4–9 days 30.1 27.2 36.7 33.8 16.0












15-24 25-34 Males 35–64 15-24
25-34 
Females 35-65
2002-03 15.0 8.6 2.8 6.8 3.7 0.8
2006-07 17.8 10.4 3.9 8.3 5.5 1.4
2010-11 17.7 13.9 4.2 8.1 3.3 0.9
2014-15 21.5 18.0 4.8 10.9 6.1 1.2
2019-20 16.3 20.6 4.6 12.8 5.7 1.4
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6.1.3 Cannabis use disorder
Cannabis use disorder (CUD) is defined as any cannabis abuse or dependence in the 
12 months prior to survey. It was measured using an instrument called the Munich-Composite 
International Diagnostic Interview (M-CIDI). The M-CIDI instrument was completed by all 
respondents reporting cannabis use in the last year. The M-CIDI combines the four cannabis 
abuse and the seven cannabis dependence criteria from  the Diagnostic and Statistical 
Manual of Psychiatric Disorders, Fourth Edition (DSM-IV).8, 9 A person who meets the criteria 
for either abuse or dependence in the 12 months prior to the survey is said to have a CUD. 
A person can be diagnosed as having either cannabis abuse or cannabis dependence. If the 
respondent meets the criteria for both abuse and dependence, then they are assigned to 
the dependence category only. In previous publications relating to the 2010–11 and 2014–15 
surveys, prevalence estimates were presented differently; those who met the criteria for both 
cannabis abuse and cannabis dependence were counted in each category. Consequently, 
the cannabis abuse results presented here for the 2010–11 and 2014–15 surveys differ to what 
was published previously.
The prevalence of CUD in 2019–20 was 1.2%, representing 45,000 of the Irish population; 
this included 0.5% with cannabis abuse and 0.6% with cannabis dependence (Table 25). The 
prevalence of CUD was 1.6% for males and 0.8% for females. The highest prevalence was 
observed among 15–34-year-olds (2.8%). Of those who had used cannabis in the last year, 
19.6% met the criteria for CUD, including 19.0% of male and 20.9% of female cannabis users.
Table 25 Prevalence of CUD in the general population, by sex and age group (%)
All adults Males Females 15–34 35–64
Cannabis abuse 0.5 0.5 0.5 1.3 0.3
Cannabis 
dependence 0.6 1.0 0.2 1.6 0.3
CUD 1.2 1.6 0.8 2.8 0.5
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
6.1.3.1 Trends in CUD
The prevalence of CUD among 15–64-year-olds increased substantially between 2010–11 
and 2014–15, from 1.5% to 3.0%, and decreased in 2019–20 to 1.4%. A decrease in CUD was 
particularly apparent among males and 15–34-year-olds (Table 26). The proportion of last 
year cannabis users with CUD was 19.6% in 2019–20, 39.2% in 2014–15, and 24.0% in 2010–11.
Table 26 Trends in CUD among 15–64-year-olds, by sex and age group (%)
All Males Females 15–34 35–64
2010–11 1.5 2.7 0.4 2.8 0.5
2014–15 3.0 4.9 1.2 5.9 0.8
2019–20 1.4 1.9 0.9 2.8 0.5
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6.1.4 Type of cannabis used
Among current (last month) users of cannabis, herbal cannabis was the most common 
type of cannabis used (80.1%), followed by resin (14.5%), hash oil (3.0%), and other types of 
cannabis (2.4%). One-quarter (25.5%) of respondents stated that the cannabis they used was 
Irish grown, 8.4% stated it was not Irish grown, and 66.1% did not know where the cannabis 
they used was grown. A joint was the most common method used to take cannabis (86.2%), 
followed by a pipe (6.5%), vaping (4.7%), eating (1.6%), and other (1.0%).
6.1.4.1 Trends in type of cannabis used
There have been changes in the type of cannabis used since earlier surveys. In the 2002–03 
and 2006–07 surveys, the majority of current users reported using resin. Between 2006–07 
and 2010–11, there was a notable increase in the use of herbal cannabis and ‘other’ cannabis 
types (Figure 24). 
 
Figure 24 Trends in type of cannabis used
*Respondents could select more than one option in the 2002–03 survey.  
Herbal includes grass, weed, skunk, and herb.  
Resin includes hash and resin.
6.1.5 Availability of cannabis
Regarding cannabis availability for people aged 15 years and older in Ireland, respondents 
reported the following in the 2019–20 survey:
•  Among all adults, 17.5% had been offered cannabis either free of charge or to buy in the 
previous 12 months; 4.8% were offered cannabis on at least 10 occasions. 
•  Recent users were asked how they got their cannabis on the last occasion they used it; 
31.2% reported sharing cannabis among a group of friends, 30.2% got it from a family 
member or a friend, and 18.0% bought it from a friend. In comparison, just 5.0% obtained 
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their cannabis from a stranger (Table 27). 
•  On the last occasion they used cannabis, recent users most frequently reported obtaining 
it at the house of a friend (38.4%), followed by obtaining cannabis in the street/park 
(18.9%), a disco/bar/club (15.3%), or a music festival (7.4%) (Table 28). 
•  The majority of recent cannabis users (89.8%) stated that it would be very or fairly easy to 
access cannabis within a 24-hour period, while 6.8% stated that it would be very or fairly 
difficult (Table 29).
6.1.6 Regular use of cannabis and efforts to stop
Among lifetime cannabis users, 32.3% stated that they had ever used cannabis regularly 
(participants defined what the term ‘regular’ meant for themselves). Respondents who had 
used cannabis regularly at some point in their lifetime were also asked about attempts to 
stop using cannabis. Of this group, 73.1% said they have managed to stop. The most common 
reason given by respondents for stopping cannabis use was that it was no longer a part of 
their social life (23.6%), followed by not wanting to use any longer (19.1%) and concerns about 
health (14.2%) (Table 30).
6.2 Ecstasy: Main findings
The main findings from the 2019–20 NDAS regarding ecstasy use include the following:
•  8.5% of respondents had ever used ecstasy in their lifetime, corresponding to 333,000 of 
the general population in Ireland aged 15 years and older. 
•  2.2% of respondents (87,000 of the general population) and 1.0% of respondents (41,000 of 
the general population) had used ecstasy in the last year and the last month, respectively.
• The average age of first ecstasy use was 19.9 years (median: 20 years). 
•  The average age of participants who reported recent ecstasy use was 25.8 years (median: 
24 years).
• The average age of first regular ecstasy use was 20.1 years (median: 20 years).
•  The proportion of respondents who personally knew somebody who used ecstasy was 
20.8%.
6.2.1 Ecstasy use by age group and sex
Ecstasy was the second most commonly used illegal drug in the year prior to the survey. 
Males were more likely than females to report recent use of ecstasy (3.2% versus 1.3%). Those 
aged 15–24 years were most likely to report recent ecstasy use (7.2%). There were significant 
sex differences in the prevalence of recent ecstasy use among those aged 25–34 years, with 





Figure 25 Recent ecstasy use, by sex and age group
6.2.1.1 Trends in recent ecstasy use
Recent ecstasy use increased from 1.1% in 2002–03 to 2.7% in 2019–20 (Figure 26). With the 
exception of the 2010–11 survey, recent ecstasy use increased at each survey. There was a 
significant decrease in 2010–11 (to 0.5%), but recent use increased to 2.1% in 2014–15. In the 
2010–11 survey, NPS were the second most commonly used illegal substance, with 3.5% of 
15–64-year-olds reporting recent use. It is possible that ecstasy was replaced by stimulant-
like NPS in the year prior to that survey. Following the introduction of the Criminal Justice 
(Psychoactive Substances) Act 2010, recent use of NPS was found to have decreased in the 
2014–15 survey to 0.8%, while recent use of ecstasy increased. 
 













15-24 25-34 35-64 65+
   All 7.2 5.8 0.4 0.0
   Males 8.9 9.7 0.4 0.0
   Females 5.4 1.9 0.3 0.0
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Recent ecstasy use among males aged 25–34 years increased from 2.2% in 2002–03 to 9.7% 
in 2019–20, with the largest increase observed between the 2014–15 and 2019–20 surveys. 
A large increase in recent ecstasy use was also observed among females aged 15–24 years; 
in the first three surveys, recent use ranged from 1.0% to 1.4%, and this increased to 3.7% in 
2014–15 and 5.4% in 2019–20 (Figure 27).
 
Figure 27 Trends in recent ecstasy use, sex by age group
6.2.2 Frequency of ecstasy use
No current users used ecstasy on 20 days or more in the previous month, which is 
considered to be daily or almost daily use. Three quarters (75.6%) had used ecstasy on 1–3 
days in the previous month, 16.4% used ecstasy on 4–9 days, while 8.0% used ecstasy on 
10–19 days. It should be noted that just 56 respondents answered this question.
6.2.3 Availability of ecstasy
Regarding ecstasy availability for people aged 15 years and older in Ireland, respondents 
reported the following in the 2019–20 survey:
•  Among all adults, 11.7% had been offered ecstasy either free of charge or to buy in the 
previous 12 months; 3.1% were offered ecstasy on at least 10 occasions. 
•  Recent users were asked how they got their ecstasy on the last occasion they used it; 
33.6% bought it from a contact they did not know personally, 22.5% shared it among a 
group of friends, and 15.2% were given it by a family member or a friend (Table 27).













15-24 25-34 35-64 15-24 25-34 35-64
Males Females
2002-03 4.2 2.2 0.0 1.4 1.2 0.0
2006-07 4.5 2.8 0.3 1.2 1.1 0.1
2010-11 1.3 0.9 0.3 1.0 0.4 0.1
2014-15 9.7 3.8 0.6 3.7 1.5 0.1
2019-20 8.9 9.7 0.4 5.4 1.9 0.3
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it at a disco/bar/club (47.7%), followed by in the street/park (10.7%) or at a music festival 
(10.6%) (Table 28).
•  The majority of recent users (85.9%) stated that it would be very or fairly easy to access 
ecstasy within a 24-hour period, while 2.3% stated that it would be very difficult (Table 29).
6.2.4 Regular use of ecstasy and efforts to stop
Among lifetime ecstasy users, 38.3% stated that they had ever used ecstasy regularly 
(participants defined what the term ‘regular’ meant for themselves). Respondents who had 
used ecstasy regularly at some point in their lifetime were also asked about attempts to 
stop using ecstasy. Of this group, 64.9% said they have managed to stop. The most common 
reason given by respondents for stopping ecstasy use was that it was no longer a part of their 
social life (44.9%), followed by not wanting to take it anymore (15.8%) and concerns about 
health (15.1%) (Table 30).
6.3 Cocaine: Main findings
The main findings from the 2019–20 NDAS regarding cocaine use include the following:
•  6.6% of respondents had ever used cocaine in their lifetime, corresponding to 260,000 of 
the general population in Ireland aged 15 years and older.
•  1.9% of respondents (72,000 of the general population) and 0.6% of respondents (23,000 
of the general population) had used cocaine in the last year and last month, respectively.
• The average age of first cocaine use was 21.9 years (median: 21 years). 
•  The average age of participants who reported recent cocaine use was 28.4 years (median: 
27 years). 
• The average age of first regular cocaine use was 23.5 years (median: 22 years). 
•  The proportion of respondents who personally knew somebody who used cocaine was 
26.7%. 
• 84.9% of lifetime users also used alcohol on the occasion of first cocaine use.
6.3.1 Cocaine use by age and sex
Males were more likely than females to report recent use of cocaine (2.8% versus 0.9%). 
Those aged 25–34 years were most likely to report recent cocaine use (5.0%). There were 
sex differences in the prevalence of recent cocaine use among those aged 25–34 years, with 
9.4% of males reporting recent use compared with 0.7% of females in the same age group 
Figure 28).
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Figure 28 Recent cocaine use, by sex and age group
6.3.1.1 Trends in recent cocaine use 
In the current survey, a statistically significant increase in recent cocaine use was observed 
for 15–64-year-olds, 15–34-year-olds, and females. Recent cocaine use among 15–64-year-
olds has increased from 1.1% in 2002–03 to 2.3% in 2019–20, although cocaine use remained 
stable between 2006–07 and 2014–15. Since the 2014–15 survey, recent cocaine use among 
males increased from 2.4% to 3.4%, and use among females increased from 0.5% to 1.1% 
(Figure 29).
 

















15-24 25-34 35-64 65+
   All 4.4 5.0 0.7 0.0
   Males 4.2 9.4 1.3 0.0
   Females 4.5 0.7 0.2 0.0
































Recent cocaine use among males aged 25–34 years increased across each survey, from 1.8% 
in 2002–03 to 9.4% in 2019–20, with the largest increase observed in the current survey. A 
large increase was also observed among females aged 15–24 years, with recent use increasing 
from 0.8% in 2014–15 to 4.5% in 2019–20 (Figure 30).
 
Figure 30 Trends in recent cocaine use, sex by age group
6.3.2 Frequency of cocaine use
One-half (51.9%) of current users used cocaine on 4–9 days in the previous month, while 
46.2% used cocaine on 1–3 days, and 1.9% used cocaine on 10-19 days. It should be noted 
that just 29 respondents answered this question.
6.3.3 Availability of cocaine
Regarding cocaine availability for people aged 15 years and older in Ireland, respondents 
reported the following in the 2019–20 survey:
•  Among all adults, 13.0% had been offered cocaine either free of charge or to buy in the 
previous 12 months; 3.5% were offered cocaine on at least 10 occasions. 
•  Recent users were asked how they got their cocaine on the last occasion they used it; 
36.1% got it from a family member or a friend, 20.5% bought it from a contact they did not 
know personally, and 18.9% shared it among a group of friends (Table 27).
•  On the last occasion they used cocaine, recent users most frequently reported obtaining 
it at the house of a friend (34.5%), followed by a disco/bar/club (28.5%), ordering it by 

















15-24 25-34 35-64 15-24 25-34 35-64
Males Females
2002-03 4.3 1.8 0.4 1.1 0.8 0.1
2006-07 4.4 3.8 0.6 2.4 1.0 0.3
2010-11 3.9 4.0 0.9 1.1 1.7 0.1
2014-15 5.1 4.4 0.6 0.8 0.8 0.3
2019-20 4.2 9.4 1.3 4.5 0.7 0.2
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•  The majority of recent users (94.5%) stated that it would be very or fairly easy to access 
cocaine within a 24-hour period, while 0.9% stated that it would be very difficult (Table 
29).
6.3.4 Regular use of cocaine and efforts to stop
Among lifetime cocaine users, 23.5% stated that they had ever used cocaine regularly 
(participants defined what the term ‘regular’ meant for themselves). Respondents who had 
used cocaine regularly at some point in their lifetime were also asked about attempts to 
stop using cocaine. Of this group, 66.8% said they have managed to stop. The most common 
reason given by respondents for stopping cocaine use was that it was no longer part of their 
social life (28.4%), followed by concerns about health (23.5%), cost (15.1%), and impact on 
job/friends/family (13.1%) (Table 30).
6.4 Cannabis, ecstasy, and cocaine tables: 
Availability and regular use







Shared among group of friends 31.2 22.5 18.9
Given by family/friend 30.2 15.2 36.1
Bought from a friend 18.0 14.9 18.0
Bought from a contact I did not 
know personally 6.5 33.6 20.5
Given by a contact I did not know 
personally 3.6 4.8 5.5
Given by a stranger 2.8 1.1 0.0
Bought from a stranger 2.2 7.9 1.1
Other 5.4 0.0 0.0
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House of a friend 38.4 9.3 34.5
Street/park 18.9 10.7 13.2
Disco/bar/club 15.3 47.7 28.5
Music festival 7.4 10.6 6.8
Ordered by phone for collection 5.3 4.8 14.4
School/college 2.1 8.7 1.3
Internet 1.9 3.1 0.0
House of a dealer 0.7 0.0 0.4
Office/workplace 0.4 0.4 0.0
Other 9.6 4.8 0.9







Very easy 62.6 73.6 52.9
Fairly easy 27.3 12.3 41.6
Neither easy nor difficult 3.3 5.8 4.6
Fairly difficult 3.8 6.1 0.0
Very difficult 3.0 2.3 0.9








No longer part of social life 23.6 44.9 28.4
Did not want to take anymore 19.1 15.8 0.0








Concern about health/health 
reasons 14.2 15.1 23.5
Did not enjoy the after-effects 11.3 8.2 3.3
Cost/could no longer afford it 6.6 4.1 15.1
Less available supply 4.3 0.0 0.0
Pregnancy 4.2 1.9 1.6
Impact on job/friends/family 3.3 2.5 13.1
Concern regarding legal 
implications if caught using by 
gardaí*
3.0 – –
The pros of taking did not 
outweigh the cons 2.4 4.5 4.5
Gave up smoking cigarettes* 2.1 – –
Persuaded by friends/family 2.0 3.1 7.7
Put on rehabilitation programme 0.2 0.0 1.6
Other 3.6 0.0 1.2
*Options only provided to those who reported regular use of cannabis
Table 31 Proportion who personally know people who use cannabis, ecstasy, or cocaine, by sex 
and age group (%)
All Males Females 15–34 35–64 65+
Cannabis 40.3 45.6 35.3 59.3 38.2 13.0
Ecstasy 20.8 24.4 17.3 40.6 14.8 2.2
Cocaine 26.7 31.4 22.1 44.3 23.2 5.0
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This chapter presents data on the use of prescribable drugs. These are drugs that can be 
legally purchased from a pharmacy or chemist, usually with a prescription. The current survey 
includes questions about the use of sedatives/tranquillisers (including benzodiazepines), 
opioid pain relievers (including over-the-counter opioids such as codeine), anabolic steroids, 
and methadone. Prevalence estimates of anabolic steroid and methadone use are presented 
here, but they are not described in further detail in this section due to the low numbers 
reporting their use.
Sedatives and tranquillisers are commonly used terms for the same group of medicines 
which depress, slow down, or calm the brain and central nervous system. They are mainly 
benzodiazepines (‘benzos’), but other drugs with the same effects (e.g. zolpidem and 
zopiclone) are included in this group. Medically they are often referred to as hypnotics, which 
induce sleep, and as anxiolytics or anti-anxiety agents.
The term ‘opioid pain relievers’ includes a number of drugs that are used to treat short-term 
and chronic pain. They are examples of opioid drugs, from the same family as morphine and 
heroin. These medicines generally require a prescription, although some codeine products 
are available over the counter from a pharmacist without a prescription; for example, 
Solpadeine and Nurofen Plus. 
A question on pregabalin use is also included in the current survey. While pregabalin is 
prescribed as a pain reliever, it is not opioid based. However, there has been concern in 
Ireland in recent years around pregabalin use due to its involvement in a relatively high 
number of fatal overdoses.10
For the first time, this survey contained questions on the non-medical use of sedatives, 
tranquillisers, and opioid pain relievers. The subset of questions included was suggested by 
the EMCDDA. Non-medical use was defined as the use of these medicines without personal 
prescription from an appropriate practitioner, taking larger doses than prescribed, taking 
these medicines for a longer period, or taking them for different purposes than prescribed. 
Data on sedative/tranquilliser use are not presented for 2002–03, as that survey asked about 
the use of either sedatives, tranquillisers, or antidepressants; subsequent surveys have asked 
about the use of sedatives/tranquillisers separately from the use of antidepressants.
The results for opioid pain relievers are not comparable with the 2002–03 and the 2006–07 
surveys and are therefore not presented here. In these surveys, the showcard for opioid pain 
relievers simply contained the word ‘codeine’, without providing any description or examples. 
Since 2010–11, the showcard for opioid pain relievers contains a comprehensive list of the 
codeine products used in Ireland.
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7.1 Prevalence of prescribable drugs
Last year prevalence (recent use) among all adults aged 15 years and older was 5.5% for 
sedatives and tranquillisers, 32.2% for opioid pain relievers, 0.1% for anabolic steroids, 
and 0.0% for methadone. More detailed tables on prevalence, with confidence intervals 
(including by sex and age group), are presented in Appendix I. The prevalence figures 
presented here and in Appendix I for sedatives/tranquillisers and opioid pain relievers relate 
to any use, including both medical and non-medical use, unless stated otherwise.
7.2 Sedatives and tranquillisers 
The main findings from the 2019–20 NDAS regarding sedative/tranquilliser use include the 
following:
•  12.7% of respondents had ever used sedatives/tranquillisers in their lifetime, 
corresponding to 499,000 of the general population in Ireland aged 15 years and older. 
•  5.5% of respondents (213,000 of the general population) and 3.2% of respondents 
(125,000 of the general population) had used sedatives/tranquillisers in the last year and 
last month, respectively.
•  0.5% of respondents (19,000 of the general population) had used sedatives/tranquillisers 
in a non-medical way in the last 12 months.
•  There was a statistically significant decrease in recent use reported by all adults (from 7.1% 
in 2014–15 to 5.5% in 2019–20).
• The average age of first sedative/tranquilliser use was 36.7 years (median: 34 years). 
•  The average age of participants who reported recent sedative/tranquilliser use was 50.9 
years (median: 49 years). 
7.2.1 Sedative/tranquilliser use by age and sex
Females were more likely than males to report recent use of sedatives/tranquillisers (6.1% 
versus 4.8%). Those aged 65 years and older were more likely than younger age groups 
to report recent sedative/tranquilliser use (8.0%). Females aged 65 years and older had 
the highest prevalence of recent use (11.5%) (Figure 31). Of those who had used sedatives/
tranquillisers in the last year, 87.2% stated that all were prescribed, 10.2% stated that none 
were prescribed, and 2.7% stated that some were prescribed while others were not.
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Figure 31 Recent use of sedatives/tranquillisers in 2019–20, by sex and age group
7.2.1.1 Trends in recent sedative/tranquilliser use
Recent use of sedatives/tranquillisers among 15–64-year-olds decreased in 2019–20 and is 
currently at 2006–07 levels. There was a small increase in recent use among males in 2019–
20. Between 2006–07 and 2014–15, females were more likely than males to use sedatives/
tranquillisers; however, following a significant decrease in female use in 2019–20, use among 
males and females is now similar (Figure 32).
 














All 15–34 35–64 65+
   All 5.5 4.0 5.5 8.0
   Males 4.8 4.1 5.5 4.1
















2006-07 2012-11 2014-15 2019-20
         All 4.7 6.5 6.1 4.9
         Males 3.7 5.7 4.4 5.0
         Females 5.7 7.3 7.7 4.8
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The main changes in recent use have occurred in males aged 65 years and older, with recent 
use almost halving between 2014–15 and 2019–20, from 8.1% to 4.1%. Among females, recent 
use decreased since 2014–15 for those aged 35–64 years (from 9.9% to 5.4%) and for those 
aged 65 years and older (from 16.5% to 11.5%) (Figure 33). 
 
Figure 33 Trends in recent sedative/tranquilliser use, sex by age group
 
In the 2006–07 and 2010–11 surveys, those aged 65 years and older were not included
7.2.2 Frequency of sedative/tranquilliser use
Two-thirds (66.7%) of those who used sedatives/tranquillisers in the last month did so on at 
least 20 days. This frequency of use was more common among those aged 65 years and older 
















15-34 35-64 65+ 15-34 35-64 65+
Males Females
2006-07 2.0 5.1 3.1 7.9
2010-11 4.6 6.5 5.0 9.1
2014-15 3.1 5.5 8.1 5.0 9.9 16.5
2019-20 4.1 5.5 4.1 3.9 5.4 11.5
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Figure 34 Frequency of sedative/tranquilliser use in the last month among current users, by sex 
and age group
7.2.3 Non-medical use of sedatives/tranquillisers
The proportion of people reporting non-medical use of sedatives/tranquillisers in the 
last year was 0.5%, with similar rates reported by males (0.6%) and females (0.4%). Males 
aged 15–34 years were most likely to report non-medical use (1.3%) (Figure 35). On the 
last occasion that respondents used sedatives/tranquillisers in a non-medical way, 54.4% 
obtained them from a friend, spouse, or relative, and 33.6% got them with a prescription that 
had been written for them. 
 
















All adults Males Females 15-34 35-64 65+
20 days 66.7 70.4 64.5 47.9 64.8 77.7
10-19 days 9.8 14.5 7.0 0.0 14.3 9.1
4-9 days 8.2 5.8 9.6 7.3 7.8 9.1


























7.3 Opioid pain relievers
The main findings from the 2019–20 NDAS regarding opioid pain reliever use include the 
following:
•  53.1% of respondents had ever used opioid pain relievers in their lifetime, corresponding 
to 1,834,000 of the general population in Ireland aged 15 years and older. 
•  32.2% of respondents (or 1,258,000 of the general population) and 13.1% of respondents 
(or 512,000 of the general population) had used opioid pain relievers in the last year and 
last month, respectively.
•  1.8% of respondents (or 70,000 of the general population) had used opioid pain relievers 
in a non-medical way in the last 12 months.
• The average age of first opioid pain reliever use was 25.1 years (median: 20 years). 
•  The average age of participants who reported recent opioid pain reliever use was 44.4 
years (median: 43 years).
7.3.1 Opioid pain reliever use by age and sex
Females were more likely than males to report recent use of opioid pain relievers (36.8% 
versus 27.3%). Recent use was most common among 35–64-year-olds (34.9%) and lowest 
among those aged 65 years and older (26.5%) (Figure 36).
 
















All 15–34 35–64 65+
All 32.2 31.0 34.9 26.5
Males 27.3 24.0 30.4 24.1
Females 36.8 38.0 39.3 28.6
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7.3.1.1 Trends in opioid pain reliever use
Recent use of opioid pain relievers significantly increased between 2010–11 and 2014–15, but 
significantly decreased in 2019–20, especially among those aged 15–34 years. However, there 
was no change in use among males aged 65 years and older (Figure 37). 
 
Figure 37 Trends in recent use of opioid pain relievers, sex by age group)
 
In the 2010–11 survey, those aged 65 years and older were not included
7.3.2 Frequency of opioid pain reliever use
One in seven (14.5%) current users used opioid pain relievers on 20 days or more in the 
previous month, which is considered to be daily or almost daily use. This was more common 
among those aged 65 years or older (38.3%) compared with 15–34-year-olds (3.7%) and 
35–64-year-olds (12.2%). Although females were more likely to use opioid pain relievers, 



















2010-11 23.1 24.8 33.4 30.3
2014-15 41.6 39.6 24.1 55.4 47.7 34.3
2019-20 24.0 30.4 24.1 38.0 39.3 28.6
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Figure 38 Frequency of opioid pain reliever use in the last month among current users, by sex and 
age group
 
7.3.3 Type of opioid pain relievers used
The most common type of opioid pain reliever used by current users in the last 30 days were 
over-the-counter (OTC) codeine products (80.2%) (Table 32). On the most recent occasion 
that current users took opioid pain relievers, 62.9% obtained them from a pharmacy in 
Ireland without a prescription, 25.6% got them using a prescription written for them, and 
7.2% got them from a friend, spouse, or relative.
Table 32 Type of opioid pain reliever used by current users in the last 30 days
Type of opioid pain reliever (N=751) %
OTC codeine products 80.2





















All adults Males Females 15-34 35-64 65+
20 days 14.5 22.1 10.7 3.7 12.2 38.3
10-19 days 11.3 15.7 9.1 9.8 9.6 18.5
4-9 days 21.5 21.9 21.4 15.9 24.7 21.2
1-3 days 52.7 40.4 58.8 70.6 53.5 22.1
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7.3.4 Non-medical use of opioid pain relievers
The proportion of people reporting non-medical use of opioid pain relievers in the last year 
was 1.8%. Those most likely to use opioid pain relievers in this way were females aged 15–34 
years (Figure 39). 
Figure 39 Recent non-medical use of opioid pain relievers 2019–20, by sex and age group
Among those who used opioid pain relievers in a non-medical way in the last year, 14.1% used 
them in this manner at least four times per week, 13.3% used them two to three times per 
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This section presents the main findings on the perceptions and attitudes of people in Ireland 
towards drug use, including tobacco and alcohol.
8.1 Attitudes towards permitting cannabis use
Respondents were asked if they agreed with permitting cannabis for medical and recreational 
use. There was a high level of agreement (88.8%) for permitting cannabis for medical use, 
with the highest level of support reported by lifetime users of cannabis (98.6%). There was 
less support (26.2%) for permitting cannabis for recreational use. Support for recreational 
use was higher among 15–34-year-olds (34.8%) compared with those aged 65 years and 
older (9.1%). Males were also more likely than females to support recreational cannabis use 
(31.1% versus 21.4%). Two-thirds of lifetime cannabis users (65.6%) agreed with permitting 
cannabis for recreational use (Table 33). 
Table 33 Support for permitting cannabis for medical and recreational use (%)
All 
adults Males Females 15–34 35–64 65+
Lifetime 
use
Medical use of cannabis
Fully agree 65.3 66.0 64.7 66.3 67.6 57.8 84.4
Somewhat agree 23.5 22.2 24.7 24.2 23.1 23.1 14.2
Neither 2.3 2.4 2.3 1.5 2.5 3.5 0.3
Somewhat disagree 2.4 2.7 2.2 2.8 1.6 4.0 0.2
Fully disagree 3.2 3.6 2.8 2.0 2.8 6.2 0.6
Don’t know 3.2 3.2 3.3 3.2 2.4 5.4 0.4
Recreational use of cannabis
Fully agree 9.3 12.6 6.0 14.3 8.6 2.2 30.6
Somewhat agree 16.9 18.5 15.4 20.5 18.2 6.9 35.0
Neither 9.3 9.4 9.2 11.5 9.0 6.3 6.3
Somewhat disagree 15.5 13.8 17.1 14.5 15.7 16.4 11.2
Fully disagree 44.7 41.0 48.3 34.3 44.1 64.8 13.2
Don’t know 4.3 4.7 4.0 4.9 4.3 3.3 3.6
Figure 40 presents the trends in attitudes of 15–64-year-olds towards permitting cannabis 
use since 2002–03. There has been an increase in support of both medical (18.4 percentage 
points) and recreational (8.7 percentage points) cannabis use. 
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Figure 40 Trends in support for permitting medical and recreational use of cannabis (15–64-year-
olds)
 
8.2 Disapproval of drug use
Respondents were asked about the extent of their approval/disapproval regarding trying 
ecstasy once or twice, trying heroin once or twice, smoking 10 cigarettes per day, and 
smoking cannabis occasionally. The proportion of respondents who reported that they either 
disapproved or strongly disapproved of each of these behaviours is presented in Table 34. For 
each of the behaviours listed in Table 34, the majority of respondents reported disapproval or 
strong disapproval, ranging from 70.9% for smoking cannabis occasionally to 95.7% for trying 
heroin once or twice. Disapproval was more common among females than males and, with 
the exception of smoking 10 cigarettes per day, increased with increasing age. Those who had 
ever engaged in the listed behaviours were less likely to report disapproval of the behaviours 
in question. One-third (33.1%) of those who had ever used cannabis reported disapproval 
for smoking cannabis occasionally, with a similar proportion of lifetime ecstasy users (35.7%) 
reporting disapproval for trying ecstasy once or twice. In comparison, two-thirds of lifetime 
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Medical use Recreational use
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Table 34 Disapproval of drug use, by sex, age, and lifetime use, 2019–20 (%)
All 
adults Males Females 15–34 35–64 65+
Lifetime 
use*
Trying ecstasy once 
or twice 83.9 80.0 87.7 73.6 86.9 93.5 35.7
Trying heroin once 
or twice 95.7 95.0 96.4 94.8 95.9 96.7 –
Smoking 10 
cigarettes per day 76.9 74.0 79.6 76.2 75.7 81.4 66.1
Smoking cannabis 
occasionally 70.9 67.5 74.2 60.2 71.5 87.8 33.1
*Due to the low number of respondents who reported lifetime heroin use, disapproval 
among lifetime heroin users is not reported for ‘trying heroin once or twice’.
 
Since 2002–03, there has been little change in the percentage of 15–64-year-olds 
reporting disapproval for trying heroin once or twice and for smoking cannabis occasionally. 
Disapproval for trying ecstasy once or twice decreased slightly in each survey, from 89.3% in 
2002–03 to 81.8% in 2019–20. Conversely, disapproval for smoking 10 cigarettes per day has 
increased with each survey, from 65.6% in 2002–03 to 75.9% in 2019–20 (Figure 41).
 

















2002-03 2006-07 2010-11 2014-15 2019-20
Trying ecstasy  
once or twice 89.3 86.9 86.6 84.7 81.8
Trying heroin  
once or twice 97.1 97.5 97.4 96.6 95.5
Smoking 10  
cigarettes per day 65.6 67.4 71.9 74.3 75.9
Smoking cannabis 
occasionally 68.8 70.5 73.0 71.6 67.2
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8.3 Perception of risk
Respondents were asked how much they thought people risk harming themselves physically 
or in other ways when they do the following: smoke one or more packs of cigarettes per 
day, binge drink, smoke cannabis regularly, try ecstasy once or twice, try cocaine once or 
twice, or try crack once or twice. The proportion of respondents who perceived great risk 
to be associated with each of these behaviours is presented in Table 35. The majority of 
respondents perceived great risk to be associated with each of the behaviours in question, 
ranging from 57.0% for smoking cannabis regularly to 82.1% for trying crack once or twice. 
Females and older respondents were more likely than males and younger respondents to 
perceive great risk for each behaviour. This was particularly evident for smoking cannabis 
regularly – just 40.9% of 15–34-year-olds perceived this to be associated with great risk, 
compared with 59.3% of 35–64-year-olds and 78.6% of those aged 65 years and older. A 
comparatively high proportion of lifetime tobacco and alcohol users reported great risk for 
using these substances compared with lifetime users of illegal drugs. Of those who had ever 
used tobacco, 59.7% perceived smoking one or more packs of cigarettes per day to be of 
great risk; in comparison, just 30.1% of lifetime cannabis users associated smoking cannabis 
regularly with great risk.
Table 35 Perception of great risk associated with tobacco, alcohol, and drug use, by sex, age, and 
lifetime use, 2019–20 (%)
All 
adults Males Females 15–34 35–64 65+
Lifetime 
use
Smoke one or more 
packs of cigarettes 
per day
62.6 58.8 66.4 56.6 64.1 68.9 59.7
Binge drink 58.8 53.7 63.8 48.7 60.5 71.8 57.5
Smoke cannabis 
regularly 57.0 51.2 62.7 40.9 59.3 78.6 30.1
Try ecstasy once or 
twice 65.6 60.0 71.0 52.8 68.7 79.0 21.5
Try cocaine once or 
twice 70.0 64.7 75.1 58.2 72.3 84.0 26.3
Try crack once or 
twice* 82.1 79.7 84.5 75.3 84.4 87.4
* Due to the low number of respondents who reported lifetime crack use, great risk among 
lifetime crack users is not reported for ‘trying crack once or twice’.
Respondents in the 2019–20 survey were less likely to perceive great risk from smoking 
cannabis regularly or trying ecstasy once or twice, but were more likely to perceive great risk 
from smoking at least one pack of cigarettes per day (Figure 42). Due to changes in question 
wording, trends are not presented for binge drink, try cocaine once or twice, or try crack 
once or twice.
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Figure 42 Trends in perception of great risk associated with tobacco, alcohol, and drug use 
(15–64-year-olds)
8.4 Perception of people addicted to drugs
Respondents were asked if they perceived a person who is addicted to drugs more as a 
criminal or more as a patient. The most common perception was ‘more as a patient’ (46.6%), 
followed by ‘both a criminal and a patient’ (24.1%), ‘neither a criminal nor a patient’ (12.5%), 
and ‘more as a criminal’ (8.8%), while 8.0% did not know or could not decide. Those who had 
ever used illegal drugs were least likely to perceive a drug addict ‘more as a criminal’ (3.6%) 
(Table 36). 
Table 36 Perception of people addicted to drugs, by sex, age, and lifetime illegal drug use (%)
All Males Females 15–34 35–64 65+
Ever used 
illegal drugs
More as a criminal 8.8 9.5 8.1 8.1 8.7 10.2 3.6
More as a patient 46.6 45.2 48.0 43.3 47.0 51.5 54.0
Neither a criminal 
nor a patient 12.5 14.0 11.2 14.5 12.8 8.4 20.3
Both a criminal and 
a patient 24.1 23.4 24.7 24.1 24.8 22.0 16.0
Don't know/cannot 
















2002-03 2006-07 2010-11 2014-15 2019-20
Smoke 1+ packs of 
cigarettes per day 59.6 59.8 60.4 67.3 61.2
Smoking cannabis 
regularly 57.2 59.6 64.0 59.9 52.3
Try ecstasy  
once or twice 77.1 68.7 65.0 64.5 62.6
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There has been a reduction in the proportion of 15–64-year-olds who perceive a person 
who is addicted to drugs more as a criminal since 2002–03 (from 16.5% to 8.5%). At the same 
time, there have been increases in the proportion of respondents who perceive a person 
who is addicted to drugs as neither a criminal nor a patient and as both a criminal and a 
patient (Table 37).
Table 37 Trends in perception of people addicted to drugs (among 15–64-year-olds) (%)
2002–03 2006–07 2010–11 2014–15 2019–20
More as a criminal 16.5 17.5 19.7 12.2 8.5
More as a patient 55.6 50.6 47.5 43.9 45.6
Neither a criminal  
nor a patient 7.7 9.3 10.8 14.3 13.4
Both a criminal and a patient 17.3 20.2 19.4 25.4 24.5
Don't know/cannot decide 2.9 2.4 2.6 4.2 8.0








Questions on the impact of drug use on local communities were included in the 2019–20 
NDAS for the first time. Specific questions on drug-related intimidation were also included, 
as the Regional Drug and Alcohol Task Forces have identified drug-related intimidation as 
being a pressing issue for many communities in Ireland. 
9.1 Problems associated with people using or 
dealing drugs
More than one-third (37.0%) of respondents stated that there was a problem with people using 
or dealing drugs in their local area, 40.2% said that there was no problem, and 22.7% did not 
know. Of those who stated that there was a problem in their local area, 35.6% said it was a very 
big problem, 46.8% said it was a fairly big problem, 13.4% said it was not a very big problem, and 
4.3% did not know. Respondents who stated that people using or dealing drugs was a very big 
or fairly big problem (30.5% of all respondents) were asked to select from the options provided 
in Table 38 what specific drug-related problems were present in their local area. The problems 
most commonly reported by these respondents were drugs being too easily available (84.4%), 
people dealing drugs (64.6%), and children and teenagers taking drugs (53.7%). 
Table 38 Problems associated with people using or dealing drugs
Weighted responses=1,756 %
Drugs being too easily available 84.4
People dealing drugs 64.6
Children and teenagers taking drugs 53.7
People taking hard drugs 41.0
People smoking cannabis in public places 39.1
Stealing, theft, or burglary related to drug use 36.8
General violent crime related to drug use or dealing 24.5
Violence between drug gangs 20.2
Begging related to drug use 19.2
Used needles (e.g. on the streets, in stair wells, in car parks) 13.2
Crack houses 9.4
Respondents could select more than one option.
Three in ten (30.5%) of respondents reported that there was a very big or fairly big problem 
with people using or dealing drugs in their local area. Those who lived in deprived areas 
were more likely to report that there was a very big or fairly big problem with people using or 
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dealing drugs in their local area (Figure 43), with 44.0% of respondents in the most deprived 
quintile reporting such problems compared with 19.7% in the least deprived quintile. 
Figure 43 Proportion of respondents reporting that people using or dealing drugs was a very big 
or fairly big problem in their local area, by area deprivation level
9.2 Drug-related intimidation
One in 10 respondents (9.9%), corresponding to 387,000 of the general population aged 
15 years and older, had either personal experience of drug-related intimidation or knew 
somebody who had been intimidated; 1.5% had personal experience of drug-related 
intimidation while 2.0% had a family member who had been intimidated because of a debt to 



























Table 39 Proportion of respondents reporting experience of drug-related intimidation
Experience of drug-related intimidation %
Personal experience of drug-related intimidation 1.5
     I have been intimidated because of a debt to a drug dealer 1.1
     I have been intimidated by drug dealers/users 0.4
A family member has been intimidated because of a debt to a drug dealer 2.0
I know people in my local area who have been intimidated because of a 
debt to a drug dealer 6.8
Someone I know has been intimidated by drug dealers/users 0.2
Other 0.1
Respondents could select more than one option.
Those who had experience of drug-related intimidation were twice as likely to live in the 
most deprived quintile (17.2%) compared with any of the less deprived quintiles (7.4–9.5%) 
(Figure 44). Respondents living in Dublin were most likely to have experience of drug-related 
intimidation (15.6%), followed by those living in the rest of Leinster (9.8%), Connaught/Ulster 
(6.3%), and Munster (6.1%). 
































The NDAS collects information on tobacco, alcohol, and drug use among the general 
population. This is the fifth such survey undertaken in the Republic of Ireland, providing an 
opportunity to observe trends over time.
The prevalence of tobacco use among survey respondents aged 15 years and older was 
found to be 17.4%, which is similar to the smoking rate (17.0%) reported in the 2019 Healthy 
Ireland Survey.11 There has been a decline in the use of tobacco in each of the five waves of 
the NDAS. A range of tobacco control policies have been implemented since the first wave 
of the NDAS in 2002–03, which may have impacted on smoking rates. These include excise 
increases, the workplace smoking ban, graphic warnings on packaging, and standardised 
(plain) packaging of tobacco.12 Our results also show that tobacco use is associated with 
deprivation; those living in the most deprived quintile were much more likely than those in 
the less deprived quintiles to report current smoking, daily smoking, and smoking at least 20 
cigarettes per day.
With respect to alcohol use, there has been little change since the 2014–15 survey, although 
the proportion of non-drinkers has increased since 2002–03, particularly among those aged 
15–34 years. Nevertheless, while one in four survey respondents indicated not using alcohol, 
more than one-half of drinkers consumed alcohol in a hazardous way, and one in five 
drinkers met the criteria for alcohol use disorder (AUD). The 2019–20 NDAS findings suggest 
that young male users of alcohol are at particular risk from their drinking patterns, with 37% 
of 15–34-year-old male drinkers meeting the criteria for AUD. These results demonstrate 
a need to fully implement the measures contained in the Public Health (Alcohol) Act 2018, 
including minimum unit pricing.
There has been no change in the prevalence of recent illegal drug use since 2014–15; however, 
there have been changes regarding the types of drugs used. While there has been a small 
decrease in the prevalence of cannabis use, the use of stimulant-type drugs (including cocaine, 
ecstasy, and amphetamines) has increased, and there has also been an increase in the use 
of LSD and poppers. Similar trends have been observed in Irish treatment data, where there 
has been a small decrease in treated cannabis use, but a considerable increase in treated 
cocaine use.13 The prevalence of recent NPS use remains very low, at 0.8% among 15–64-year-
olds (compared with 3.5% in 2010–11), perhaps highlighting the continued impact of the 
Criminal Justice (Psychoactive Substances) Act 2010, which made the sale, import, export, or 
advertisement of unregulated psychoactive substances for human consumption illegal. The 
Act also gave appropriate powers to An Garda Síochána and the Courts to intervene quickly to 
prevent trade in a non-criminal procedure via the use of prohibition and closure orders.
Compared with previous surveys, those who reported illegal drug use were more likely to 
report the recent use of two or more illegal substances. In the current survey, 25.0% reported 
having used at least three illegal drugs in the last year compared to 15.4% in 2014–15. The 
2019–20 NDAS also asked about the use of two or more substances (including alcohol) on the 
same occasion. Alcohol was the drug most commonly used with cannabis, cocaine, and ecstasy. 
This was particularly apparent among recent cocaine users (93.4%). In addition, among those 
who had ever used cocaine, 84.9% reported that they had also used alcohol on the occasion 
of their first cocaine use. Given the increased risk of both physical and psychological harm 
associated with polydrug use, it will be important to monitor these trends going forward and to 
develop harm reduction initiatives in order to reduce polydrug use and avert harm.
Males were more than twice as likely as females to report recent use of an illegal drug, except 
in the youngest age group (15–24 years), in which there was little difference between illegal 
drug use among males and females. Participants in the 15–24-year-old age group were also 
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those who reported the highest prevalence of use for each illegal drug, except for cocaine 
and NPS. The cohort that reported the highest level of recent drug use was males aged 25–
34 years, of whom one in four had used an illegal drug in the last year. The median age at first 
use of the most commonly used illegal drugs was found to have increased slightly compared 
with the 2002–03 survey.
While recent cannabis use among males decreased overall between 2014–15 and 2019–20, 
cannabis prevails as the most popular illegal drug in the population, while its use among 
males aged 25–34 years has continued to increase. Of survey respondents who had used 
cannabis in the last year, nearly one in five were found to meet the criteria for cannabis use 
disorder (CUD), although there has been a noticeable decrease in CUD among males and 
15–34-year-olds since the last survey. Ecstasy was the second most commonly used illegal 
drug in the year prior to the survey; the largest increase in ecstasy use was seen among 
males aged 25–34 years, with almost 1 in 10 males in this age group having used ecstasy in 
the last year. A similar proportion of this cohort had used cocaine in the last year, with males 
being more likely to report recent cocaine use than females. Noticeable increases in cocaine 
use were also observed among females aged 15–24 years. Overall, recent cocaine use was 
found to have increased significantly among 15–64-year-olds since 2014–15.
There has been much debate in Ireland around the liberalisation of cannabis laws, and 
legislation was passed in 2019 to allow for the Medical Cannabis Access Programme to come 
into operation in Ireland on a pilot basis for 5 years. There was strong agreement among 
survey respondents for permitting cannabis for medical use (88.8%), but far less support 
for permitting cannabis for recreational use (26.2%). The majority of respondents reported 
disapproval or strong disapproval for smoking cannabis regularly (70.9%), with more than 
one-half (57.0%) perceiving great risk to be associated with smoking cannabis regularly. 
Regarding prescribable drugs, there were significant decreases in recent use of both 
sedatives/tranquillisers and opioid pain relievers. The prevalence of sedative/tranquilliser 
use is currently at 2006–07 levels. In 2018, the Health Service Executive Medicines 
Management Programme published the document Guidance on appropriate prescribing of 
benzodiazepines and z-drugs (BZRA) in the treatment of anxiety and insomnia.14 In terms of 
legislative requirements, the Misuse of Drugs Regulations 2017 update had implications for 
benzodiazepines and z-drugs. It is possible that these changes in practice and legislation 
have impacted on the prevalence of sedative/tranquilliser use. However, it is less clear why 
we have seen a significant decrease in opioid pain reliever use.
Questions on the impact of drug use on local communities were included in the 2019–20 
NDAS for the first time. More than one-third of respondents stated that there was a 
problem with people using or dealing drugs in their local area. Those who lived in deprived 
areas were more likely to report that there was a very big or fairly big problem with people 
using or dealing drugs in their local area, with 44.0% of respondents in the most deprived 
quintile reporting such problems compared with 19.1% in the least deprived quintile. One 
in 10 respondents had either personal experience of drug-related intimidation or knew 
somebody who had been intimidated. Those who lived in the most deprived quintile were  
twice as likely to experience drug-related intimidated when compared with those in the least 
deprived quintile. While people living in deprived areas are no more likely than those living 
in less deprived areas to use illegal drugs, our results indicate that people living in the most 
deprived areas are disproportionately negatively impacted by drug use activities.
When interpreting the results presented in this report, it is important to consider them in 
the context of the survey’s strengths and limitations. The NDAS is a large national survey 
that is representative of the Irish population; it has been undertaken five times using the 
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same methodology and model questionnaire developed by the EMCDDA. In addition, data 
collection was conducted by a large and experienced survey-based marketing research 
company and all researchers were thoroughly trained with reference to a standard 
operating procedures manual. We can therefore be confident that our results are valid and 
provide reliable prevalence estimates for comparison with the previous waves of the NDAS 
conducted in Ireland. In addition, the 63.9% response rate is high by international standards. 
However, there are several limitations which should also be noted. The sampling frame 
utilised by the NDAS only includes private households and consequently does not allow for 
people in prison or other institutionalised individuals, homeless individuals, or Travellers to 
be included, potentially excluding adults who may be more likely than the general population 
to use drugs. As the survey did not make a specific provision for interviews to be conducted 
in languages other than English this may have impacted on the participation of non-Irish 
respondents. Although the NDAS includes questions on the prevalence of heroin and crack 
cocaine use, the numbers included in the sample are too small for reliable prevalence 
estimates. Therefore, it will be necessary to complement this survey by using other methods, 
such as the capture-recapture method or the multiplier method, to estimate the prevalence 
of high-risk drug users. The NDAS may also be subject to non-response bias, however, it is 
not possible to ascertain any demographic (except for region of residence) or socioeconomic 
information on those who did not participate. Drug prevalence questions are considered to 
be sensitive and therefore people may refuse to participate or under-report their drug use. 
NDAS results were based on self-reports that may be influenced by reporting or recall bias. 
Due to restrictions arising from Covid-19, fieldwork was curtailed before the target sample 
was achieved. The proportion of achieved interviews (5,762) was 87.8% of the initial target 
(6,560). The target number of completed interviews was only achieved in two of the RDATF 
areas and the response rate was particularly low in the North Dublin area (41.0%). 
Ireland’s national drug strategy adopts a health-led approach and is based on sound 
epidemiological data and an understanding of the extent, patterns, and consequences of 
psychoactive substance use from a public health perspective. This information is made 
available through an extensive monitoring system that provides data and analysis on 
prevalence, treatment demand, and other epidemiological indicators, such as estimates of 
hidden drug use. In recent years researchers have used innovative tools for estimating drug 
use and observing patterns of drug use behaviours, such as wastewater analysis and online 
surveys, to complement the traditional epidemiological tools.  
The effective implementation of drug policy depends on accurate estimates of the level of drug 
use within the population that this policy is designed to benefit. Population surveys based on 
continuing developments in epidemiological research provide reliable data on drug prevalence, 
the nature of drug use and its distribution across age groups and sexes. When repeated, these 
surveys enable policymakers to observe trends over time, an essential insight when measuring 
the effectiveness of interventions and predicting what phenomena will need attention in 
the future. Ireland’s NDAS includes estimates of problematic use of alcohol and cannabis, 
information that will be useful to service planners’ decisions on future treatment needs. It also 
presents detailed information on public attitudes and perceptions regarding drugs and the 
impact of the illicit drug markets on communities. This provides a perspective on Irish society’s 
thinking on drug issues, and on how the drug situation affects people’s lives indirectly. 
The findings in this report will add to policy-makers’, service providers’ and the general 
public’s understanding of the drug phenomenon. It will be a key support in the ongoing 
development of an evidence-informed response to this continually changing feature of 
contemporary life.





Appendix I Tables:  
Prevalence of drug, alcohol, and tobacco use
Table 40 Prevalence of drug, alcohol, and tobacco use among all adults aged 15 years and older, 
by drug type





Any illegal drug 23.0 (21.6–24.3) 7.4 (6.6–8.2) 4.1 (3.5–4.8)
Cannabis 20.7 (19.4–22.0) 5.9 (5.1–6.7) 2.9 (2.4–3.5)
Ecstasy 8.5 (7.6–9.4) 2.2 (1.8–2.8) 1.0 (0.8–1.4)
Cocaine (including crack) 6.9 (6.0–7.7) 1.9 (1.5–2.4) 0.6 (0.4–0.9)
Cocaine powder 6.6 (5.8–7.4) 1.9 (1.5–2.3) 0.6 (0.4–0.9)
LSD 4.8 (4.2–5.5) 0.9 (0.6–1.2) 0.4 (0.3–0.7)
Magic mushrooms 4.7 (4.1–5.4) 0.4 (0.3–0.7) 0.1 (0.0–0.2)
Amphetamines 4.0 (3.4–4.7) 0.8 (0.6–1.2) 0.2 (0.1–0.4)
Poppers 3.9 (3.3–4.5) 1.4 (1.1–1.8) 0.9 (0.6–1.2)
NPS 2.0 (1.6–2.5) 0.6 (0.4–0.9) 0.2 (0.1–0.4)
Solvents 1.7 (1.3–2.1) 0.0 (0.0–0.1) 0.0 (0.0–0.0)
Crack 0.6 (0.4–0.9) 0.2 (0.1–0.4) 0.0 (0.0–0.1)
Heroin 0.3 (0.1–0.5) 0.0 (0.0–0.1) 0.0 (0.0–0.0)
Opioid pain relievers 53.1 (51.5–54.7) 32.2 (30.7–33.6) 13.1 (12.0–14.2)
Sedatives and tranquillisers 12.7 (11.7–13.8) 5.5 (4.7–6.2) 3.2 (2.7–3.8)
Anabolic steroids 0.3 (0.2–0.6) 0.1 (0.0–0.3) 0.0 (0.0–0.2)
Methadone 0.1 (0.1–0.3) 0.0 (0.0–0.2) 0.0 (0.0–0.1)
Alcohol 80.4 (79.1–81.6) 74.2 (72.8–75.6) 61.8 (60.2–63.3)
Tobacco 42.9 (41.4–44.5) 20.2 (18.9–21.5) 17.8 (16.5–19.0)
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
CI = confidence interval
When the figure 0.0% is reported, it can mean that either no respondents reported use of 
the drug or that a very low number reported use and that due to rounding it is presented 
as 0.0%. Confidence intervals are only provided after 0.0% if there are observations in 
the category. Where there are no confidence intervals, this means that there were no 
observations.
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Table 41 Prevalence of drug, alcohol, and tobacco use among 15–64-year-olds, by drug type





Any illegal drug 27.1 (25.5–28.8) 9.0 (7.9–10.0) 4.9 (4.2–5.8)
Cannabis 24.4 (22.8–26.0) 7.1 (6.2–8.1) 3.4 (2.8–4.2)
Ecstasy 10.3 (9.2–11.5) 2.7 (2.2–3.4) 1.3 (0.9–1.8)
Cocaine (including crack) 8.3 (7.3–9.3) 2.3 (1.8–3.0) 0.7 (0.5–1.1)
Cocaine powder 8.1 (7.1–9.1) 2.3 (1.8–2.9) 0.7 (0.5–1.1)
LSD 5.7 (4.9–6.6) 1.1 (0.7–1.5) 0.5 (0.3–0.8)
Magic mushrooms 5.7 (4.8–6.5) 0.5 (0.3–0.9) 0.1 (0.0–0.3)
Amphetamines 4.8 (4.0–5.6) 1.0 (0.7–1.5) 0.3 (0.1–0.5)
Poppers 4.7 (4.0–5.6) 1.7 (1.3–2.3) 1.1 (0.7–1.5)
NPS 2.5 (1.9–3.1) 0.8 (0.5–1.2) 0.3 (0.1–0.5)
Solvents 2.0 (1.6–2.6) 0.0 (0.0–0.2) 0.0 (0.0–0.0)
Crack 0.7 (0.5–1.1) 0.2 (0.1–0.4) 0.0 (0.0–0.2)
Heroin 0.3 (0.2–0.6) 0.0 (0.0–0.2) 0.0 (0.0–0.0)
Opioid pain relievers 54.7 (52.8–56.5) 33.4 (31.6–35.2) 13.1 (11.8–14.3)
Sedatives and tranquillisers 11.8 (10.6–13.0) 4.9 (4.2–5.8) 2.4 (1.9–3.1)
Anabolic steroids 0.4 (0.2–0.7) 0.1 (0.0–0.3) 0.0 (0.0–0.2)
Methadone 0.2 (0.1–0.4) 0.1 (0.0–0.2) 0.0 (0.0–0.2)
Alcohol 83.0 (81.6–84.4) 77.7 (76.1–79.2) 65.3 (63.6–67.1)
Tobacco 42.4 (40.6–44.3) 22.3 (20.8–23.9) 19.5 (18.0–21.0)
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
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Table 42 Prevalence of drug, alcohol, and tobacco use among 15–34-year-olds, by drug type 





Any illegal drug 31.8 (28.6–35.0) 17.7 (15.1–20.4) 9.8 (7.8–11.9)
Cannabis 27.3 (24.2–30.4) 13.8 (11.4–16.2) 6.5 (4.8–8.2)
Ecstasy 13.7 (11.3–16.1) 6.5 (4.8–8.2) 3.1 (2.1–4.6)
Cocaine (including crack) 10.6 (8.5–12.7) 4.8 (3.6–6.6) 1.5 (0.9–2.6)
Cocaine powder 10.5 (8.4–12.6) 4.7 (3.4–6.4) 1.4 (0.8–2.5)
LSD 6.6 (4.9–8.4) 2.4 (1.5–3.7) 1.3 (0.7–2.4)
Magic mushrooms 4.9 (3.6–6.6) 1.0 (0.5–2.0) 0.3 (0.1–0.9)
Amphetamines 5.6 (4.0–7.2) 2.3 (1.5–3.6) 0.7 (0.3–1.5)
Poppers 7.8 (5.9–9.6) 4.1 (2.9–5.7) 2.4 (1.5–3.7)
NPS 4.2 (3.1–5.9) 1.9 (1.2–3.1) 0.7 (0.3–1.5)
Solvents 2.4 (1.6–3.8) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Crack 0.9 (0.5–1.9) 0.4 (0.1–1.1) 0.1 (0.0–0.6)
Heroin 0.4 (0.1–1.1) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Opioid pain relievers 50.2 (46.7–53.6) 31.0 (27.8–34.2) 12.3 (10.1–14.6)
Sedatives and tranquillisers 7.8 (5.9–9.6) 4.0 (2.8–5.6) 1.8 (1.1–2.9)
Anabolic steroids 0.7 (0.3–1.6) 0.1 (0.0–0.7) 0.0
Methadone 0.2 (0.1–0.8) 0.1 (0.0–0.7) 0.1 (0.0–0.6)
Alcohol 80.3 (77.5–83.0) 76.5 (73.6–79.5) 63.2 (59.9–66.6)
Tobacco 32.7 (29.5–35.9) 25.6 (22.5–28.6) 21.0 (18.2–23.8)
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
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Table 43 Prevalence of drug, alcohol, and tobacco use among 35–64-year-olds, by drug type  





Any illegal drug 24.2 (22.4–26.0) 3.5 (2.8–4.3) 1.9 (1.4–2.6)
Cannabis 22.6 (20.8–24.3) 2.9 (2.3–3.8) 1.5 (1.1–2.1)
Ecstasy 8.3 (7.1–9.4) 0.4 (0.2–0.7) 0.1 (0.0–0.4)
Cocaine (including crack) 6.9 (5.8–8.0) 0.8 (0.5–1.3) 0.3 (0.1–0.6)
Cocaine powder 6.6 (5.5–7.6) 0.7 (0.5–1.2) 0.3 (0.1–0.6)
LSD 5.1 (4.2–6.1) 0.2 (0.1–0.5) 0.0 (0.0–0.0)
Magic mushrooms 6.1 (5.1–7.1) 0.3 (0.1–0.6) 0.0 (0.0–0.0)
Amphetamines 4.2 (3.5–5.2) 0.2 (0.1–0.5) 0.0 (0.0–0.0)
Poppers 2.8 (2.2–3.6) 0.3 (0.1–0.6) 0.2 (0.1–0.6)
NPS 1.3 (0.9–1.9) 0.1 (0.0–0.3) 0.0 (0.0–0.0)
Solvents 1.8 (1.3–2.4) 0.0 (0.0–0.2) 0.0 (0.0–0.0)
Crack 0.6 (0.3–1.0) 0.1 (0.0–0.3) 0.0 (0.0–0.0)
Heroin 0.3 (0.1–0.6) 0.0 (0.0–0.3) 0.0 (0.0–0.0)
Opioid pain relievers 57.5 (55.4–59.6) 34.9 (32.9–36.9) 13.5 (12.1–15.0)
Sedatives and tranquillisers 14.3 (12.8–15.8) 5.5 (4.5–6.4) 2.8 (2.2–3.6)
Anabolic steroids 0.1 (0.1–0.4) 0.1 (0.0–0.3) 0.0 (0.0–0.2)
Methadone 0.2 (0.1–0.4) 0.0 (0.0–0.2) 0.0 (0.0–0.0)
Alcohol 84.8 (83.2–86.3) 78.4 (76.7–80.2) 66.7 (64.6–68.7)
Tobacco 48.5 (46.4–50.6) 20.3 (18.6–22.0) 18.6 (16.9–20.2)
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
Main findings
99
Table 44 Prevalence of drug, alcohol, and tobacco use among males aged 15–64 years, by drug 
type  





Any illegal drug 32.8 (30.3–35.3) 12.3 (10.6–14.0) 7.0 (5.7–8.4)
Cannabis 29.5 (27.1–32.0) 9.9 (8.3–11.5) 5.0 (3.9–6.2)
Ecstasy 14.8 (12.9–16.7) 3.9 (3.0–5.0) 1.9 (1.3–2.8)
Cocaine (including crack) 11.6 (9.9–13.3) 3.5 (2.7–4.7) 1.3 (0.8–2.0)
Cocaine powder 11.2 (9.5–12.8) 3.4 (2.6–4.5) 1.2 (0.8–2.0)
LSD 8.7 (7.2–10.2) 1.8 (1.2–2.6) 0.9 (0.5–1.5)
Magic mushrooms 8.6 (7.1–10.1) 0.9 (0.5–1.5) 0.2 (0.1–0.6)
Amphetamines 7.3 (5.9–8.7) 1.5 (1.0–2.3) 0.4 (0.2–0.9)
Poppers 7.4 (6.0–8.8) 3.0 (2.2–4.0) 1.8 (1.2–2.6)
NPS 3.7 (2.8–4.9) 1.2 (0.7–1.9) 0.4 (0.2–0.9)
Solvents 3.1 (2.3–4.2) 0.0 (0.0–0.3) 0.0 (0.0–0.0)
Crack 1.1 (0.7–1.8) 0.3 (0.1–0.7) 0.1 (0.0–0.4)
Heroin 0.6 (0.3–1.1) 0.0 (0.0–0.4) 0.0 (0.0–0.0)
Opioid pain relievers 50.3 (47.6–53.0) 27.9 (25.5–30.3) 8.4 (6.9–9.9)
Sedatives and tranquillisers 10.9 (9.2–12.5) 5.0 (3.9–6.2) 2.2 (1.5–3.1)
Anabolic steroids 0.5 (0.3–1.1) 0.2 (0.1–0.6) 0.0 (0.0–0.3)
Methadone 0.3 (0.1–0.8) 0.1 (0.0–0.5) 0.0 (0.0–0.4)
Alcohol 84.5 (82.6–86.4) 79.8 (77.7–82.0) 68.6 (66.2–71.1)
Tobacco 46.2 (43.5–48.8) 26.0 (23.7–28.4) 23.5 (21.3–25.8)
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
based on valid responses.
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Table 45 Prevalence of drug, alcohol, and tobacco use among females aged 15–64 years, by drug 
type  





Any illegal drug 21.6 (19.4–23.7) 5.7 (4.4–6.9) 2.9 (2.1–3.9)
Cannabis 19.3 (17.2–21.4) 4.4 (3.4–5.6) 2.0 (1.3–2.8)
Ecstasy 6.0 (4.7–7.2) 1.6 (1.1–2.4) 0.6 (0.3–1.2)
Cocaine (including crack) 5.1 (3.9–6.2) 1.2 (0.7–1.9) 0.4 (0.2–0.9)
Cocaine powder 5.0 (3.9–6.2) 1.1 (0.7–1.8) 0.2 (0.1–0.6)
LSD 2.8 (2.0–3.8) 0.3 (0.1–0.8) 0.2 (0.1–0.6)
Magic mushrooms 2.8 (2.0–3.8) 0.2 (0.1–0.6) 0.1 (0.0–0.5)
Amphetamines 2.2 (1.6–3.2) 0.5 (0.3–1.1) 0.1 (0.0–0.4)
Poppers 2.1 (1.4–2.9) 0.5 (0.2–1.0) 0.1 (0.0–0.4)
NPS 1.2 (0.8–1.9) 0.4 (0.2–0.8) 0.0 (0.0–0.0)
Solvents 0.9 (0.6–1.6) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Crack 0.3 (0.1–0.8) 0.1 (0.0–0.5) 0.1 (0.0–0.5)
Heroin 0.1 (0.0–0.4) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Opioid pain relievers 59.0 (56.4–61.6) 38.8 (36.2–41.3) 17.6 (15.6–19.6)
Sedatives and tranquillisers 12.7 (11.0–14.5) 4.8 (3.8–6.1) 2.7 (1.9–3.6)
Anabolic steroids 0.2 (0.1–0.6) 0.1 (0.0–0.4) 0.0
Methadone 0.1 (0.0–0.4) 0.0 0.0
Alcohol 81.6 (79.6–83.6) 75.6 (73.3–77.8) 62.1 (59.6–64.6)
Tobacco 38.7 (36.2–41.3) 18.7 (16.6–20.7) 15.5 (13.6–17.4)
All figures are based on weighted data, are rounded to the nearest decimal place, and are 
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Appendix II Tables: Trends in lifetime, last year, 
and last month prevalence of drug, alcohol, 
and tobacco use
This appendix presents trends in the prevalence of drug, alcohol, and tobacco use for the 
five waves of the National Drug and Alcohol Survey (NDAS) which have been undertaken to 
date. As the first three surveys collected data on 15–64-year-olds only, trends for the five 
time points are presented for this age group.
There have been some changes in question wording and in the information provided on the 
showcards, which may impact on the comparability of some measures between surveys. 
These changes are as follows:
•  Opioid pain relievers: In the 2002–03 and 2006–07 surveys, the showcard for opioid 
pain relievers simply contained the word ‘codeine’ without providing any description or 
examples. Since 2010–11, the showcard for opioid pain relievers contains a comprehensive 
list of the codeine products used in Ireland. Consequently, tests of statistical significance 
for differences between the first three surveys are not reported for opioid pain relievers.
•  Tobacco and alcohol: Minor changes in question wording and the calculation for last 
month use of both tobacco and alcohol were introduced in the 2014–15 survey. 
•  Sedatives and tranquillisers: No prevalence figures are presented for sedatives and 
tranquillisers for 2002–03, as that survey asked about the use of either sedatives, 
tranquillisers, or antidepressants; subsequent surveys have asked about the use of 
sedatives/tranquillisers separately from the use of antidepressants.
‘Any illegal drug’ refers to cannabis, ecstasy, cocaine powder, magic mushrooms, 
amphetamines, poppers, LSD, new psychoactive substances (NPS), solvents, crack, and 
heroin. In the 2010–11 survey, questions on NPS were included for the first time but were not 
included in the ‘any illegal drug’ grouping as NPS only became illegal following the Criminal 
Justice (Psychoactive Substances) Act 2010. In order to ensure comparability with the 
2014–15 and 2019–20 surveys in our trends analysis, we have reclassified NPS as an illegal 
drug for the 2010–11 survey. This means that there may be discrepancies between the results 
published here and those published in previous NDAS reports.
Changes that are found to be statistically significant are reported. When considering the 
results, it should be borne in mind that statistical significance does not imply that the change 
is of practical importance. The tests of statistical significance are used to establish the 
degree of confidence with which we can infer that the observed changes in drug prevalence 
between surveys are not due to sampling error. A significance level of 5% has been specified, 
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